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Female lupus prone NZM2410 estrogen receptor alpha (ERα) functionally deficient 
(ERαKO) mice are protected from renal disease and have prolonged survival compared to 
wild type (WT) littermates, however the mechanism of protection is unknown. 
Plasmacytoid dendritic cells (pDCs) and type I interferon (IFN) drive lupus pathogenesis 
and estrogen acting via ERα enhances both pDC development and IFN production. The 
objectives for this work were to determine if ERα modulates pDC number, maturation, or 
function in pre-disease NZM2410 mice as a possible protective mechanism of ERα 
functional deficiency in lupus prone mice. We measured the effect of ERα functional 
deficiency on spleen pDC frequency, number, maturation, activation state, and type I IFN 
activity. ERα functional deficiency reduced the frequency of MHCII+ pDCs without 
altering overall pDC frequency, number, or maturation state. Additionally, ERαKO 
NZM2410 mice had significantly decreased numbers of pDCs expressing PDC-TREM, a 
modulator of toll-like receptor (TLR) mediated IFN production.  ERαKO NZM2410 mice 
also had reduced endogenous spleen type I IFN activity. After in vitro TLR9 stimulation, 
ERα functional deficiency significantly reduced the expression of PDC-TREM on pDCs 
from both NZM2410 and C57BL/6 mice.  pDCs from ERαKO mice had reduced levels of 
PDC-TREM transcripts prior to TLR stimulation, suggesting that ERα signaling alters the 
pDC’s potential to respond to TLR stimulation, thus ‘pre-programming’ the pDCs.  Since 
PDC-TREM is required for pDC TLR mediated IFN production, this finding represents a 
mechanism by which ERα impacts pDC IFN production. Thus, we have identified a 
significant effect of ERα functional deficiency on pDCs and type I IFN activity in pre-
disease NZM2410 mice. We believe the modulation of PDC-TREM expression in pDCs 
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and resultant type IFN activity may represent a mechanism by which ERα functional 
























Chapter 1: Rationale and Background 
 
The relationship between the sex bias of systemic 



























Female ERαKO NZM2410 mice have prolonged survival compared to WT 
NZM2410 mice [1]. The ERαKO mice survive longer because they do not develop as 
severe glomerulonephritis, measured by albuminuria and renal pathology [1]. Although 
the ERαKO mice do not develop clinical kidney disease, autoantibody production and 
renal immune complex deposition are similar to levels in WT NZM mice [1]. These 
findings suggested the primary impact of the functional loss of ERα function was on the 
local tissue response to inflammation or the immune cell response to inflammatory 
signals (e.g. autoantibodies and immune-complexes).  
Dendritic cells (DCs) are activated by immune-complexes and act as a bridge 
between the innate and adaptive immune responses [2]. DCs consist of two major 
subsets, the classical DC (cDC) and plasmacytoid DC (pDC). In lupus, DCs (both pDCs 
and cDCs) impact disease pathogenesis and progression [3, 4]. Mechanistically, dendritic 
cells (DCs) express Fc receptors, which bind and subsequently internalize immune-
complexes [2]. The nuclear material (e.g. DNA and RNA) in lupus autoantibody 
containing immune-complexes stimulates endosomal toll-like receptors (TLRs) [2]. TLR 
stimulation results in DC activation and cytokine production, which in turn activates T 
and B cells in an amplification loop of inflammation [2]. 
pDCs are of particular interest in SLE because they produce the type I IFNs. Type 
I IFN signature genes are elevated in patients with SLE and the levels correlate with 
disease activity [5]. Furthermore, IFN therapy can induce a lupus like syndrome as a side 
effect. Studies in lupus prone mice have further demonstrated the importance of type I 
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IFNs and pDCs in disease [5]. The absence or blockade of type I IFN ameliorates disease 
in multiple mouse models [6-8]. Additionally, both partial and transient absence of pDCs 
prevents clinical disease in mouse models of lupus [9, 10].  
In addition to pDCs being central in lupus pathogenesis, estrogen and ERα 
modulate pDC development and function [11-14]. Estrogen influences DC development 
and function primarily via ERα [12, 14]. Estrogen via ERα alters both Flt3L and GM-
CSF mediated bone marrow derived in vitro DC development [11]. We previously 
published that ERα deficient GM-CSF mediated bone marrow derived DCs, from lupus-
prone mice, are less responsive to TLR stimulation in vitro, consistent with previous 
studies in non-autoimmune mice [15]. Regarding type I IFN, long-term exposure to in 
vivo estrogen, via ERα, enhances the type I IFN response of human and murine pDCs in 
response to TLR stimulation [16]. Given, ERα’s role in pDC development and function 
we are interested in the impact of ERα signaling on pDCs in normal immunity and in 
SLE. 
In this work, we investigated the effect of ERα signaling in vivo and in vitro on 
pDC number, development, activation, and function in B6 and NZM2410 mice before 









I hypothesized that ERα signaling positively impacted pDC number and 




















Aim I Aim II 
Aim III 
ERα signaling increased pDC number and activity in lupus prone mice 
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1.3 Background 
1.3.1. Lupus Pathogenesis 
 Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease 
characterized by the presence of antinuclear autoantibodies [17]. Although SLE may 
affect virtually every organ system, symptoms and organ involvement varies widely 
among individuals. Common symptoms include fatigue, fever, arthritis, skin rash, and 
renal disease [17].  The prevalence of SLE is 20 to 150 cases per 100,000. However, 
women account for 90% of cases, making the prevalence rates in women increase to 164 
to 406 per 100,000. The exact etiology of disease is unknown and is likely multifactorial 
[17]. Genetic, environmental, immunologic, and hormonal factors are implicated in 
disease [17]. Regarding genetics, GWAS studies have identified over 50 genetic loci 
containing polymorphisms that increase risk for SLE. Of these loci, the polymorphisms in 
the major histocompatibility (MHC) locus are the most common and increase the risk of 
SLE most significantly [17]. Environmental factors associated with increased risk for 
disease include viruses, UV light, silica dust, and medications [17]. SLE patients have 
numerous immunologic abnormalities and it has proven difficult to separate 
abnormalities responsible for disease from abnormalities caused by disease. One 
immunological hallmark of lupus is the production of anti nuclear antibodies, which may 
occur years prior to onset of clinical symptoms [17]. These antibodies bind to self-nuclear 
material to form immune complexes. The immune complexes deposit in tissue and 
activate both immune and stromal cells [18]. For this reason, it is tempting to attribute 
tissue damage to immune complex deposition. However, the presence of immune 
complexes is not the complete immunological picture, as many people with anti nuclear 
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antibodies do not develop clinical symptoms of lupus [17].  Therefore a second level for 
immune dysregulation must occur to induce clinical disease. This second immune 
dysregulation may occur in cells of the innate immune system [18]. Innate immune cells 
contribute directly to tissue injury, release cytokines, and activate autoreactive T and B 
cells [18]. One mechanism by which the adaptive and innate immune cells communicate 
in SLE is by innate immune cell uptake of immune complexes. The uptake of immune 
complexes activates innate immune cells and perpetuates the inflammatory response. 
Since autoantibody production and immune complex deposition alone are not sufficient 
to cause disease, it is likely that aberrant activation of the innate immune cells by immune 
complexes represents the second level of immune dsyregulation required for organ 
damage.  
 
1.3.2 SLE sex bias 
SLE affects women at a nine to one ratio compared to men. Additionally, disease 
incidence is highest during the reproductive years [19]. Based on this epidemiologic data, 
the sex hormones and their receptors are thought to play a role in disease.  
 
Sex hormone levels Many studies have examined levels of sex hormones in disease and 
during flares. These studies have yielded contradictory results. However, a meta-analysis 
concluded that female SLE patients have reduced DHEA, progesterone, and testosterone 
and increased estradiol and prolactin [20]. Male patients may have increased prolactin 
and possibly a reduction in DHEA. Male SLE patient’s levels of testosterone and 
estrogen are normal [20].  
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Estrogen Receptor expression in SLE  In PBMCs from lupus patients, RNA and protein 
levels of ERα are increased compared to healthy controls [21, 22]. ERβ transcripts were 
decreased in SLE PBMCs compared to controls [21]. In a study of 22 female lupus 
patients and 17 controls, T cells from SLE patients had a slight (non significant) decrease 
in ERα and the same levels of ERβ compared to controls [23]. However, SLE T cells 
expressed higher levels of calcineurin and CD154 in response to ERα and ERβ agonists 
compared to controls, suggesting SLE T cells are more responsive to estrogens than 
healthy T cells [23].  
 
Exogenous estrogen The effects of exogenous estrogens can be divided into two 
categories. The first category is the effect of exogenous estrogens on disease 
development and the second is the effect of exogenous estrogens on disease activity.  
 Development of SLE: The effects of estrogen containing oral hormonal 
contraceptives and hormone replacement therapy have also been controversial in disease. 
The past use of estrogen containing oral contraceptive was shown to be associated with a 
significant increase (1.9 fold) of developing lupus [24]. In a later case control study, a 
rate ratio of 1.19 (95% CI 0.98-1.45) was associated with any use of combined oral 
contraceptive (estrogen and progesterone) [25]. The greatest risk was found in newly 
started short term use (<3 months) with a rate ratio of 2.52 (95% CI 1.13-5.57) [25]. 
Additionally, there was an increased rate of SLE in women receiving high dose of ethinyl 
estradiol (50ug) compared to women receiving medium (31-49ug) and low (<30) doses of 
ethinyl estradiol [25]. 
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 SLE activity: Regarding the effect of estradiol on SLE activity, the results have 
also been controversial, however, in a large double-blind prospective study the use of oral 
contraceptives was found not to increase the risk of flares in women with SLE [26]. 
Hormone replacement therapy was not shown to increase risk of severe flares, but does 
significantly increase mild/moderate disease flares [26].  
 
SLE and menstrual cycle 
  
 Based on self-reported data, 36% of women with SLE flare prior to menses [27]. 
Additionally, menstrual cycle disorders are observed in 50% of SLE patients [28]. 
 
Selective estrogen receptor modulators; tamoxifen and raloxifene: 
In NZB/NZW F1 mice, tamoxifen improves disease [29]. However, in a small (n=11) 
human double-blind crossover trial, tamoxifen did not improve disease [30]. Regarding 
raloxifene, in NZB/W F1 mice, raloxifen administration protects mice from estradiol 
mediated autoreactivity [31]. In a double-blind randomized control trail of menopausal 
women with SLE, raloxifene improved bone density in SLE patients without increasing 
SLE activity [32]. In this study, a there was a slight, but non significant, reduction in 
disease flares and activity in the raloxifene group compared to placebo [32]. 
 
Selective estrogen receptor down-regulator; Fulvestrant: 
In a double-blind and placebo-controlled study, the effects of fulvestrant were studied 16 
premenopausal women with moderate SLE over a 1 year period [33]. In the group 
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receiving the fulvestrant, patients were able to reduce the dose of prednisone, 
hydroxychloroquine, and azathioprine compared to the control group [33]. 
 
DHEA: DHEA has been studied in randomized controls trials for lupus and has been 
shown to be moderately beneficial [26, 34].  The use of DHEA, current SERMs, and 
SERDs are not widely accepted as a viable treatment option due to side effects and lack 
of large studies.  
 
Mouse models: In lupus mouse models, estrogen treatment accelerated disease and 
androgen treatment improved disease [35]. Additionally, ovariectomized female mice had 
delayed onset of disease and the castration and estrogen treatment of male mice caused 
disease to progress similar to female mice [35]. In the NZB/W mice have a strong sex 
bias, with the females progressing faster than male nice. The NZM2410 mice also have a 
sex bias towards the female mice, however, this sex bias is weaker than the NZMB/W 
background [36]. The absence of functional ERα in female NZM2410 mice reduced 
kidney disease and increased survival [1]. Protection was not provided by the absence of 
ERβ [1]. The absence of functional ERα or ERβ in male mice did not provide protection, 
however, this may be due to the male mice not developing severe disease at the time of 
sacrifice as there were trends toward decreased disease in ERalpha deficient mice (32 





1.3.3 Dendritic cell biology 
The term dendritic cell (DC) encompasses two types of cells, the plasmacytoid 
dendritic cell (pDC) and classical dendritic cell (cDC). Briefly, pDCs express endosomal 
toll-like receptors 7 and 9 (TLRs) [37]. When the TLRs are stimulated by their ligands, 
typically viral DNA/RNA, pDCs produce large amounts of type I IFNs [37]. The type I 
IFN function to alert the innate and adaptive immune systems to the presence of 
infection. Through this mechanism pDCs play an important role in viral immunity. The 
specifics of pDC biology will be described in the following chapters. Here, we will 
review the basic functions of cDCs. cDCs are best known as antigen-presenting cells that 
induce a primary immune response [2]. cDCs endocytose antigens of foreign and self 
origin and present these antigens to T cells via MHCI or MHCII. cDCs also express T 
cell co-stimulatory molecules (CD80/86) and produce signal three cytokines (IL-12) [2].  
Depending on the environment and quality of the antigen, cDCs can induce a Th1 or Th2 
response or immunologic tolerance [2]. Although all cDCs function to present antigen, 
the term cDC encompasses many subtypes of DCs, each with specialized function. Due 
to the plasticity of DC populations, DC ontogeny is complex. Most basically, cDCs can 
be diveded into five categories; Lymphoid CD8+ DCs, lymphoid CD11b+ DCs, tissue 
CD103+CD11b- DCs, inflammatory CD11b+ DCs, and migratory DCs. The DC 
subtypes differ in their expression of pattern recognition receptors, location, and 
regulators. Lymphoid CD8+ DCs live in the lymphoid tissue (spleen) and are best known 
for sampling the blood for microbial stimuli and presenting antigens (and cross 
presenting) to CD8+ T cells via MHCI [38]. Tissue CD103+CD11b- DCs share the 
MHCI presentation function with the lymphoid CD8+ DCs, however they live outside of 
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the spleen and sample the environment of a specific tissue [35, 38]. Lymphoid CD11b+ 
cells also reside in the lymphoid tissue and act as a viral sensor. Upon viral stimulation, 
they secrete high levels of cytokine and present antigen via MHCII [38]. Inflammatory 
CD11b+ cells are thought to arise from both the DC lineage and monocyte lineage [38]. 
Their maturation is induced by inflammation and are present only during an active 
inflammatory response [32]. Migratory DCs live in tissue and mature and migrate to the 
draining lymph node upon stimulation with microbial products. They play a role in 
antigen presentation and tolerance [38].  
 
Dendritic cells in SLE 








[39]. Once the 
immune complex 
binds the Fc 
receptor pDCs 
endocytosis the 
Diagram 2  Dendritic cells  in lupus pathogenesis 
Pascual et al, 2003 
DCs promotes lupus pathogenesis by producing IFN alpha, presenting 
self antigens, and activating T and B cells 
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immune complex. Inside the cells the nucleic acid portion of the immune complex 
stimulates endosomal TLRs (TLR7/9). TLR stimulation results in activation of the pDC 
to produce IFNα. The IFNα activates T, B, NK, and classical dendritic cells (cDCs) [39]. 
cDCs take up apoptotic cells and can inappropriately stimulate autoreactive T and B cells 
[4]. Additionally, cDCs can function in the organs to facilitate tissue damage [40]. 
Scheme 1 from Pascual et al. summarizes the role of pDCs and cDCs in lupus 
pathogenesis [4].  Although we began describing the role of pDCs in lupus pathogenesis, 
it is unclear what cell type initiates the cycle of inappropriate immune activation. Since 
lupus pathogenesis involves multiple levels of immune dysregulation, disease is probably 
initiated/perpetuated by dysfunction in multiple cells types.  
 DC dysfunction has been noted in lupus prone animals [41]. Additionally, DC 
dysfunction is noted in human SLE. Although the conclusions from these studies are 
complicated by differences in DC isolation and culture systems, cDC and pDC 
abnormalities in cytokine production, activation, and number are present in SLE patients 
(addressed in chapters 2 and 3).  The requirement of DCs for disease progression in mice 
was shown by the deletion of DCs in multiple lupus prone mouse strains [3, 9, 10].  In 
MRL/lpr mice, the constitutive deletion of CD11c+ cells (cDCs and pDCs) prevented 
renal damage [3]. Although the deletion of CD11c+ cells protected the mice from clinical 
manifestations of lupus (i.e. renal damge), renal immune complex deposition was 
unchanged in the DC deficient animals compared to controls [3]. Therefore, DCs likely 
play a role in perpetuating organ damaged caused by immune complexes without 
hindering the production of autoantibodies or the deposition of immune complexes. 
Recently, two papers have shown the deletion of pDCs alone ameliorated disease in lupus 
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prone mice. Both the transient deletion of pDCs and the haplodeficiency of pDCs reduced 
disease in lupus prone mice [9, 10].  These deletion studies in mice have confirmed the 
importance of pDCs in lupus pathogenesis. 
 
Plasmacytoid Dendritic Cells in SLE 
Plasmacytoid dendritic cells (pDC) impact lupus pathogenesis [42]. In SLE, 
autoantibodies form immune complexes with self nucleic acids. pDCs take up the 
immune complexs via Fc Receptors and respond to the self nucleic acids in the immune 
complexes primarily through toll-like receptors (TLRs) [16]. Once the TLRs are 
stimulated, pDCs produce inflammatory cytokines, including type I interferon (IFN).  
pDCs rapidly produce type I interferon (IFN) in quantities  200 to 1,000 times more than 
other cell types [43]. Other cell types including PMNs also make IFNalpha.  Though on a 
per cell basis, pDCs produce significantly more IFNalpha than PMNs, due to their being 
significantly more PMNs than pDCs leads to uncertainty regarding the contribution of 
one cell type vs another in the pathogenesis of lupus. Type I IFNs activate DCs, NK, B 
and T cells to increase cytokine production and antigen presenting capacity resulting in 
activation of the body’s innate and adaptive immune responses [44, 45]. Type I IFNs can 
cause loss of self-tolerance as evidenced by development of a reversible drug-induced 
lupus like disease in patients treated with IFNα for hepatitis C [46]. Type I IFN serum 
levels are elevated in SLE and correlate with disease activity [46]. Mouse models have 
solidified the importance of both type I IFNs and pDCs in disease. In lupus prone mice, 
the expression of an IFN gene signature in myeloid and lymphoid cells precedes disease 
onset [47].  Additionally, systemic treatment with IFNα of lupus prone mice exacerbated 
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disease by inducing serve glomerulonephritis [48]. The deletion of the type I IFN 
receptor protects NZB and NZM2328 lupus prone mice from disease [6, 7]. In the 
NZM2328 model the disease protection provided by the absence of IFN signaling was 
correlated with decrease function of cDCs [7]. In BXSB mice, which have a duplication 
of the TLR7 gene, treatment with an anti-IFN-alpha/beta receptor antibody reduced 
kidney disease and increased survival [8]. These human and murine studies support the 
hypothesis that type I IFN signaling plays an important role in SLE. Two IFNα 
monoclonal antibodies are being tested in SLE patients, sifalimumab and rantalizumab 
[49]. These antibodies partially reduced IFN signature gene expression in peripheral 
blood mononuclear cells and skin [49]. Additionally, sifalimumab improved skin and 
joint symptoms [49]. However, sifalimumab was less effective in reducing the IFN 
signature gene expression in patients with severe disease (mean SELDAI score of 11) and 
similar findings were produced with rontalizumab treatment. .  In the end, neither of these 
drugs reached their primary endpoints and were thus “failures”.  Trial design and dosing 
may have overshadowed a positive drug effect.   The partial effectiveness of these drugs 
suggest it may be more powerful to more effectively block Type I interferon activity to 
achieve therapeutic benefit.. However, more complete blockade of type I IFN signaling 
may impair the ability of the body to flight viral infections such as seen with some kinase 
inhibitors used in RA. Therefore, to create more effective therapies we must better 
understand type I IFN signaling in SLE and the mediators of its effect. 
 
Dendritic Cells and Estrogen 
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 Mouse and human immune cells express estrogen receptors. In mice, mature B 
and NK cells expression both ERα and β [50]. T cells, pDCs, cDCs, and macrophages 
express only ERα [50]. In humans, B cells express the highest amount of ERα [50]. 
pDCs, T cells, NK cells, and monocyte derived DCs express intermediate levels of ERα 
[50]. Monocytes express the lowest levels of ERα [50]. ERβ is expressed by B cells and 
pDCs [50]. 
 A few studies have looked at sex differences in expression of estrogen receptors. 
Monocytes from premenopausal women express less ERα compared to monocytes from 
men and postmenopausal women [50]. However, no differences have been detected in T 
cells, B cells, or pDCs [50].  
Mouse DCs are obtained by culturing BM with either GM-CSF or Flt3L. Both 
cytokines are important for DC development in vivo. GM-CSF drives DC generation 
during inflammation and Flt3L generates DCs during the steady state [51]. BM cells are 
cultured with GM-CSF to obtain a population of CD11chi CD11b+ DCs that resemble the 
monocyte derived inflammatory DCs (iDC).  BM can also be cultured with Flt3L to 
obtain mDCs, LDCs, and 
pDCs. The cell 
populations obtained 
from the Flt3L culture 
system represent the 
steady state DC 
populations found in the 
spleen [52]. Both of 
Diagram 3  ERα’s impact on GMCSF mediated DC 
development 
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ERα positively regulates expression of MHCII, CD86, CD40 
and inflammatory cytokine production by GMCSF mediated 
derived DC by promoting IRF4 transcription 
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these!  culture systems are regulated by estrogen. Regarding GM-CSF driven BM DC 
cultures, the addition of estradiol preferentially promotes the generation of 
CD11chiCD11bint cells that express high levels of MHCII and CD86 (Scheme 2) [13].  
Furthermore, estradiol signaling promotes the generation of fully functional iDCs [12]. 
The iDCs cultured in the absence of estradiol signaling express less MHCII and CD86 
expression after TLR4 stimulation and they produce less inflammatory cytokines upon 
engagement of CD40 [12] (Scheme 2). The effect of estradiol was specifically found to 
be through ERα regulation of IRF4 transcription [12-14] (Scheme 2).  In contrast to GM-
CSF BM cultures, estradiol via ERα reduces DC numbers from Flt3L driven BM DC 
cultures, suggesting estradiol differently regulates each DC subset [11]. Regarding pDCs, 
estradiol/ERα signaling increases pDC production of IFNα in response to TLR7/9 
stimulation [16, 53]. Although, the majority of studies were carried out in B6 mice, one 
study has looked into the effect of estradiol on BMDC cultures from lupus prone mice. 
This study found the addition of estradiol to BMDC cultures from young (predisease) 
mice reduced BMDC inflammatory responses, however, when estradiol was added to 
BMDC cultures from mice with clinical disease the estradiol enhanced the inflammatory 
responses [54]. This study suggests lupus disease activity impacts estradiol’s role in DC 
function. However, more studies are needed to understand estrogen’s impact on dendritic 
cells in the setting of autoimmunity and inflammation. Additionally, studies have almost 
exclusively studied the role of estrogen in DC development and function using in vitro 
culture and in vitro stimulation. Therefore, more works needs to be done to understand 
how estradiol/ERα alters in vivo DC development and function.  
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1.3.4 NZM2410 Mice 
The NZM2410 mice were created by mating the litter mates from a NZB/WF1 cross with 
NZW mice [36]. The NZM2410 mice have a weak gender bias towards female mice, 
produce IgG anti-ds DNA, and die of immune complex mediated glomerulonephritis by 6 
months of age [36]. The genetics of the NZM2410 mouse has been studied extensively. 3 
lupus susceptibility loci were identified in the NZM mice [36]. These loci have been 
individually crossed onto B6 mice to study their role in disease. Loci 1, sle1, contributes 
to the production of autoreactive B and T cells and the production of autoantibodies. Sle2 
causes B cell hyperactivity. Sle3 decreases levels of activation-induced cell death of 
CD4+ cells [36]. Based on these studies, it was determine that the likelihood of 
developing disease is dependent on the number and balance between susceptibility and 
resistance alleles [36].  Variations in the murine susceptibility genes have been identified 
in human SLE. Some of the alleles include complement receptor 2, SLAM family 











1.3.5 Model of ERα deficiency 
 The ERα ‘deficient’ mice used for this work and in most other studies of ERα deficiency 
are not null for ERα [55]. The ERα deficient (ERαKO) mice were produced by inserting 
a neo cassette into exon 2 and the mouse expresses an N terminal truncated chimeric ERα 
protein lacking the 
activation function 1 
(AF-1) domain, but 
retaining the activation 
function 2 (AF-2), DNA 
binding, and ligand 
binding domains [55] 
(Scheme 3). The 
truncated ERα protein in 
the knockout mice resembles both the endogenously expressed ERα46 splice variant and 
the AF-1 null ERα mutant (Scheme 3). Both ERα46 and AF-1 null isoforms have a 
functional impact in immune cells, including DCs. Seillet et al. showed that the AF-1 
domain is differentially required for DC development [56]. The AF-1 domain is required 
for steady state DC development and early stages of inflammatory DC development, 
however, it is dispensable at later stages of inflammatory DC development [56]. 
Regarding the endogenously expressed ERα46 splice variant, monocyte to macrophage 
transition induces ERα46’s expression, which correlates with MHCII expression on these 
cells [57].  ERα46 is also expressed by human T, B and NK cells [58]. Based on this 




function and potentially impact disease as well as the immunological findings presented 
in this article.  As the relative contribution of the lack of an AF1 domain versus the 
possible function of a truncated ERα are delineated, it is important to understand the 
mechanisms by which this relative “ERα deficiency” is protective in lupus and impacts 
DC activity in normal immunity and autoimmunity. Since the ERαKO is not a true 






































Chapter 2: Impact of estrogen receptor 




























2.1 Introduction  
Dendritic cell populations 
During the steady state in vivo there are three DC populations in mouse lymphoid 
organs. The populations are pDCs and two subsets of CD11c+ DCs (cDCs). The cDCs are 
further divided into CD11b+ and CD8a+ cDCs. pDCs produce large amount of type I 
IFNs in response to viral infection, CD8a+ cDCs present antigen to CD8+ T cells, and 
CD11b+ cDCs produce inflammatory cytokines and present antigen to CD4+ T cells 
[38]. Additionally, during the steady state there are tissue resident DCs, which function to 
present antigen in the lymph node [59]. During the steady state DC differentiation is 
dependent on Flt3L [52]. Endothelial cells, mast cells, T cells, and bone marrow 
fibroblasts, and IFNy differentiated macrophages produce Flt3L [60-62]. However, other 
cellular sources likely exist, particularly during the inflammatory state. In an 
inflammatory state, GM-CSF drives the development of a different type of DC, the 
inflammatory DC (iDC) [38, 51]. iDCs  develop from GR-1+ monocytes and produce Il-
12 and induce the differentiation of antigen-specific Th1 cells [51]. GM-CSF is produced 
by endothelial cells, fibroblasts, mast cells, macrophages, and T cells [63]. Bacterial 
endotoxins, IL-6, IL-1 and TNFa can induced GM-CSF production [64].  Flt3L and GM-
CSF are used in vitro to culture DC populations from BM hematopoietic progenitor cells. 
Flt3L driven cultures produce lymphoid organ steady state DCs (mDCs/CD11b+, 
LDCs/CD8a+, and pDCs) and GM-CSF driven cultures produce iDCs [52]. Traditionally 
Flt3L is thought to be responsible for steady state DC development and survival, as DCs 
generation is impaired in Flt3L KO mice. However, recent evidence suggests Flt3L also 
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impacts DC response during infection [65]. Flt3L is produced and released by mast cells 
in response to infection and the Flt3L release mediates the expansion of the CD8+ cDC 
subsets [65]. Furthermore Flt3L is increased in the synovial fluid and serum of 
rheumatoid arthritis patients and the absence of Flt3L protects mice from developing 
collagen induced arthritis [66, 67]. This finding highlights the complexity of DC 
regulation in vivo and the need to study the DC populations in vivo under 
inflammatory/disease conditions to best understand their function in disease.  
 
Dendritic cells in SLE 
DC populations in SLE patients have been studied, however, the results are 
inconsistent. The inconsistences are likely due to differences in isolation and culture of 
the DC subsets as well as confounders found in all studies of patients based on disease 
severity, disease length and medications as well as individual variability.  According to 
multiple early studies, SLE patients have reduced numbers of blood pDCs. The blood 
number are likely reduced because the pDCs have infiltrated the effected organs [5]. 
pDCs are found in both human lupus skin and kidney lesions [5, 68]. However, some 
studies have identified normal to increased levels of pDCs in the blood from SLE patients 
[41]. Regarding cDCs, studies have reported low to normal levels of cDCs in the blood of 
SLE patients [7]. Difficulties in identifying and isolating human DCs confounded these 
studies. Thus, new technologies and a better understanding of DC biology will help to 
accurately identify and understand the role of DCs in SLE. In murine lupus, one study 
reported pDC and cDC frequencies and numbers are increased in the spleen due to 
increased homing to the spleen during disease [69]. Another study found increased 
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CD11c+ cells in the spleens of lupus mice [70].  However, this area has not been 
extensively studied and the markers used in these studies were not specific. Therefore, 
more work must be done to identify DCs in lupus prone mice.   
 
 ERα and DC development 
 Estrogen via ERα impacts both GM-CSF and Flt3L mediated development of 






of iDCs by both 
increasing the 
number of iDCs 
generated and the 
inflammatory 
potential of the 
iDCs [12, 13]. In vivo, estradiol/ERα signaling also promotes the development of 
CD11c+CD11b+ iDCs [51]. During culture with Flt3L ERα signaling takes on 2 roles. 
The first role is to reduce numbers of hematopoietic progenitor  cells [11]. The second is 
to promote the development of fully functional DCs [11]. Therefore estradiol decreases 
the overall number of DCs produced in Flt3L cultures and promotes the function of the 
Diagram 5 ERα’s impact on GMCSF and Flt3L mediated DC 
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Flt3L DC numbers decreased by ERα signaling 
GM-CSF DC numbers increased by ERα signaling   
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remaining DCs. Thus, ERα signaling is important for the number and function of DCs. 
However, more work is needed to understand how ERα signaling impacts DC 
populations in vivo. Additionally, DC populations should be studied during inflammation, 
as the role of ERα differs in the inflammatory state compared to the steady state.  
 Our laboratory found that ERα signaling positively impacts GM-CSF mediated 
BM cultures from lupus prone mice [15]. The impact was more profound in DCs derived 
from lupus prone mice compared to B6 control mice. To further understand ERα’s role in 
lupus prone DC development the work presented in this paper investigates ERα’s impact 
on DCs generated from Flt3L cultures from lupus prone mice and pDC populations 
present in vivo both prior to and after the development of clinical disease.  
 
Plasmacytoid dendritic cell development 
pDCs develop from common DC progenitors (CDP) and common lymphoid 
progenitors (CLP) that are Flt3+c-Kithigh. In addition to pDCs, CDPs also yield cDCs and 
CLPs yield T, B, and NK cells [37]. No pDC specific progenitor has been identified. 
Flt3L drives the proliferation and maturation of the common progenitors and the survival 
of mature pDCs [37]. Interestingly, the pDCs are more sensitive to changes in Flt3L 
levels compared to cDCs [37]. Flt3L signaling in pDCs has not been studied extensively, 
but it likely signals through PI3K activation of mTOR [37]. pDCs are also more sensitive 
to rapamycin (mTOR inhibition) than cDCs. Once pDCs develop to maturity they do not 
proliferate. pDC life span is poorly understood. 
Molecularly, pDC fate is determined by the expression of the basic helix-loop-
helix transcription factor E2-2 [71]. pDCs require E2-2 to develop and to maintain their 
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pDC status [72]. If E2-2 is absent in a mature pDC they will begin to express the cDC 
transcription factor Id2 and develop a cDC phenotype [72]. Mechanistically, E2-2 
promotes the transcription of pDC specific genes and represses expression of cDC 
specific genes [72].  
pDCs develop to maturity in the BM and acquire the surface expression of the 
pDC specific receptor Ly49Q [73]. Ly49Q expression denotes pDCs as mature in the BM 
and is required for optimal IFNα production [74]. Once mature, the pDCs exit the BM 
and populate peripheral lymphoid organs via the blood stream [75].  pDC exit of the bone 
marrow is dependent on the transcription factor Runx2, which control expression of the 
















Since pDCs impact lupus pathogenesis and ERα signaling alters in vitro Flt3L 
mediated pDCs development in healthy mice, I hypothesize ERα signaling impacts the 
frequency, number, activation, and function of pDCs in pre-disease NZM2410 mice. 
These changes in pDCs may account for the disease protection of ERα deficiency in 
















Diagram 6  











ERα signaling increases plasmacytoid and myeloid DCs in Flt3L driven BM cultures 
from NZM2410 mice  
 
ERα impacts in vitro DC development in Flt3L driven BM cultures from B6 mice, but the 
effect of ERα on Flt3L driven BM cultures from other strains and specifically lupus-
prone mice is not known [11, 56]. To assess the impact of ERα signaling on DC 
populations in lupus prone mice, we cultured BM from WT and functionally mutated 
ERα  (ERαKO) female NZM2410 (NZM) mice with Flt3L to produce bone marrow 
derived DCs (BMDCs). We identified the standard BMDC populations of pDC, myeloid 
DC (mDC), and lymphoid DC (LDC) populations by flow cytometry. We studied post-













































Figure 1. DC populations in Flt3L 
driven BMDC cultures. BM from WT 
and ERαKO 10-14 week old female 
NZM2410 and B6 mice was cultured 
with 10% Flt3L for 7 days under low 
estrogen conditions. The functional 
mutant of ERα reduced the percent of 
pDCs (B220+CD11c+) and mDCs 
(CD11c+, B220-, CD11b+) without 
altering the percent of LDCs (CD11c+, 
B220-,CD11b-) obtained from the BM 
cultures in both NZM (A) and B6 (C). 
Flow cytometry plots representative of 
3 separate experiments; totaling 6 
animals per genotype (B, D). Cultures 
from NZM ERαKO mice generated a 
reduced cell yield and cultures from B6 
ERαKO mice generation increased cell 
yield compared to WT (E). Results are 
expressed as the median ±IQR. 
Statistical analysis performed with 
Mann-Whitney analysis.  
17.55±1.4 10.10±0.58 
!
7.5±0.62 13.9±1.6 5.35±0.6 13.82±2.1 
24.6±2.2 20.7±1.3 
13.5±3.4 10.3±0.82 8.3±1.3 5.0±0.99 















! p = 0.0043
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pubertal pre-disease (10-14 week) NZM mice to improve the likelihood of identifying a 
change in DC populations responsible for disease development rather than a secondary 
change caused by the disease environment. Only female mice were studied based on our 
prior description that the functional mutation of ERα provides protection from disease  in 
females [1]. Additionally, we cultured the cells under low estrogen conditions, using 
charcoal/dextran treated FBS in phenol red-free media to reduce variability caused by 
differing levels of estrogen in FBS and the ERα stimulating capacity of phenol red. Using 
this system, we found that BM cultures from ERαKO NZM mice, compared to WT 
littermates, had a lower percentage of pDCs (CD11c+B220+) and mDCs 
(CD11c+CD11b+B220-), while maintaining a similar percentage of LDCs 
(CD11c+CD11b-B220-) (Figure 1A and B). The same trend, although to a lesser extent, 
was observed in Flt3L driven BMDCs from age and sex matched B6 control mice (Figure 
1C and D). This finding suggests the functional mutant of ERα reduced the total yield of 
cells obtained from NZM BM cultures (Figure 1E), consistent with previous results in 
GM-CSF driven cultures. We calculated total yield of cells by determining the ratio of 
the number of cells recovered on day 7 of culture compared to the number cells placed in 
culture on day 0. The yield of cells from cultured BMDCs was reduced in ERαKO mice 
and this effect was restricted to BMDCs from NZM mice. In B6 control animals, 
functional ERα signaling reduced the cell yield (Figure 1E). These data suggest the 
impact of ERα signaling on in vitro Flt3L driven BMDC culture development and/or 
survival is strain and/or disease specific. However, ERα’s impact on the percentage of 
DC populations was consistent between NZM and B6 BMDCs. The impact of ERα 
signaling on DC populations was consistent with previous findings in B6 animals [11]. 
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Overall, our findings suggest that ERα impacts the final stages of Flt3L driven DC 
production regardless of disease status, however, ERα differentially impacts proximal 
stages in Flt3L driven DC production depending on disease state.  
 
The functional mutation of ERα increased apoptosis in Flt3L driven BM cultures from 
NZM mice 
 










































































































































Figure 2. Apoptotic 
cells in Flt3L driven 
BMDC cultures. BM from 
WT and ERαKO 10-14 
w e e k  o l d  f e m a l e 
NZM2410 was cultured 
with 10% Flt3L for 7 days 
u n d e r l o w e s t r o g e n 
conditions. Cultures from 
E R α K O m i c e  h a d 
increased frequencies of 
apoptotic cells compared 
to cultures from WT mice 
(A). Flow cytometry plots 
r e p r e s e n t a t i v e o f 3 
separate experiments; 
totaling at least 6 animals 
per genotype (A). 
Figure 2 cont. The total number of cells continuously increased over days 5 to 7 of culture and 
the frequencies of live cells, pDCs, and cDCs remain constant between genotypes over days 5 
to 7 (B). Results are expressed as the median ±IQR. Statistical analysis performed with Mann-




ERαKO NZM mice, we measured the frequency of apoptotic and dead cells on day 7 of 
culture. Flt3L derived BM cultures from ERαKO NZM mice had an increased frequency 
of apoptotic cells (annexinV+) compared to WT cultures (Figure 2A). This finding 
indicates that in Flt3L driven NZM BM cultures the functional mutation of ERα increases 
apoptosis, which may explain the reduced cell yield. Since the change in apoptosis, 
although significant, is small, we do not believe an increase in apoptosis accounts for the 
total reduction in cell yield.!  Therefore it is likely that the ERαKO cells have impaired 
development, since mature DCs do not proliferate. Alternatively, lupus DCs are known to 
be ‘overactive’ thus they may be reaching Flt3L induced maturation earlier than healthy 
DC. As a result, we may be missing their peak development in culture by harvesting at 
the same time as DCs from B6 mice. To determine if the lupus DCs were maturing early 
we harvested Flt3L driven BM cultures from WT and ERαKO NZM mice at days 5, 6, 
and 7 post sacrifice and measured total cell yield as well as frequency of each DC 
subtype. We found that the NZM Flt3L driven BM cultures do not develop early, as day 7 
had the highest cells yield (Figure 2B). Additionally, the frequency of DC populations 
did not change between days, indicating that reduced cell yield is not due maturational 
changes in a specific DC subtype (Figure 2B). This finding indicates that the reduction in 
cell yield in NZM Flt3L driven BM cultures is not due to rapid development followed by 
cell death. Instead, the reduced cell yield is likely due to both alterations in DC precursor 





NZM mice have an altered distribution of pDCs in vivo compared to B6 controls 
   
To determine if there was a difference in pDC populations between NZM and B6 
mice, we measured pDCs frequency and number in the BM and spleens of pre-disease 
(12-14 week) female NZM mice and B6 age and sex matched control mice. pDCs were 
identified as (B220+, CD11b-, SiglecH+); the gating strategy is displayed in Figure 3. We 
found that NZM mice had reduced frequencies and numbers of pDCs in the BM 
compared to B6 mice (Figure 4A). The NZM mice, however, had increased frequencies 
and numbers of pDCs in the spleen compared to B6 mice (Figure 4B). This finding 
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Figure 3. Flow cytometry gating strategy for pDCs. Total spleen cells from a WT NZM2410 
mouse. Cells were serially gated as follows, singlets to live to CD11b- B220+ to SiglecH+ (A). Spleen 
cells from a WT and ERαKO female NZM2410 mouse showing mPDCA1 and SiglecH expression on 




with more pDCs subsiding in the spleen and less remaining in the BM (their organ of 
origin).  
 We hypothesized pDCs from NZM mice exit the BM early and enter the  
periphery as immature pDCs. To test this hypothesis we measured the maturity of the 
spleen pDCs by measuring expression of the maturation marker Ly49Q. There was no 
change in the frequency of pDCs expressing the Ly49Q maturation marker in the spleens 
of NZM compared to B6 mice, indicating there is no difference in spleen pDC maturation 
status in NZM mice (Figure 5B). This finding suggests the pDCs from NZM mice are not 
exiting the BM as immature cells, but rather fully mature pDCs. Based on this evidence, 
we hypothesized NZM mice have a reduced percent of mature pDCs in the BM due to 
increased egress of mature pDCs from the BM. To test this hypothesis we measured 
Ly49Q expression on BM pDCs. NZM mice have a significantly lower frequency pDCs 













Figure 4. pDC frequency and number in the BM and spleen of B6 and NZM2410 10-14 week old female mice.  
Frequency and number of pDCs (B220+CD11b-SiglecH+) in BM of B6 and NZM mice (A). Frequency and number of 
pDCs (B220+CD11b-SiglecH+) in the spleens of B6 and NZM mice (B).  Flow cytometry plots represent data from at least 
4 separate experiments, which are summarized in the graphs (C), B6 (n≥5) and NZM (n≥7). Results are expressed as the 
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female NZM mice the mature BM pDC population exits the BM at a higher rate than 
mature pDCs from B6 mice. The increased egress from the BM could explain the 
increase of spleen pDC number in NZM mice. Additionally, since this work was 
preformed in pre-disease lupus prone mice, the increase in mature peripheral pDCs may 
contribute to SLE pathogenesis.  Future work should investigate the mechanism of this 
increased egress of mature pDCs from the BM.  We also measured the number of cDCs 
in the spleens of B6 and NZM2410 10-14 week old female mice. We did not see any 
change in the frequency and number of cDCs in the spleens of NZM mice compared to 
B6 (Figure 6). However, we did see a reduction in the intensity of MHCII staining in 
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Figure 5. Frequency of Ly49Q+ pDCs in the BM and Spleens of B6 and NZM2410 10-14 week old female 
mice.  Frequency of Ly49Q+ pDCs (B220+CD11b-SiglecH+) in BM of B6 and NZM mice (A). Frequency and 
number of Ly49Q+ pDCs (B220+CD11b-SiglecH+) in the spleens of B6 and NZM mice (B).  Flow cytometry 
plots represent data from at least 4 separate experiments, which are summarized in the graphs (C), B6 (n≥5) 
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ERα signaling did not alter the frequency of pDCs in the spleens and bone marrow of 
lupus prone mice 
 
Based on others and our in vitro data, we hypothesized functionally mutated ERα 
would reduce the percent and number of pDCs in the bone marrow and spleens of pre-
disease lupus-prone mice in vivo.  To assess the impact of ERα on DC numbers in NZM 
mice, we identified pDCs  (CD11b-B220+siglecH+) and the cDC population (B220-, 
siglecH-, CD11c+, MHCII+) in the spleens of WT and ERαKO pre-disease (10-14 week 
old) female mice. In contrast to the in vitro effects of ERα, the in vivo the mutation of 
functional ERα had no effect on the frequency or total number of spleen pDCs or cDCs in 
either NZM (Figure 7A and Figure 8) or B6 mice (Figure 9 and Figure 10). To confirm 
the accuracy of our pDC identification, as inflammation can alter the expression of the 
pDC markers mPDCA1 and SiglecH, we showed that the siglecH+ cells represented a 
single and overlapping population of cells with the mPDCA1+ population in the NZM 
mice (Figure 3B) [76]. 
Since pDCs develop to maturity in the bone marrow, we also measured the 
frequency and absolute number of pDCs in the bone marrow of WT and ERαKO NZM 
mice. Although, ERα deficiency did not alter the percent of pDCs in the BM of the NZM  






























Figure 6. Frequency and number of cDCs in the spleens of B6 and NZM2410 10-14 week old female mice.  
Frequency and number of cDCs (B220—SiglecH-CD11c+MHCII+) in the spleens of B6 and NZM mice (A). Flow 
cytometry plots represent data from at least 4 separate experiments, which are summarized in the graphs (C), 
B6 (n≥6) and NZM (n≥10). Results are expressed as the median ±IQR. Statistical analysis performed with 







 mice, ERα deficiency reduced the absolute number of BM pDCs (Figure 7B). The 
reduction in pDC absolute number was due to a decrease in the overall bone marrow 
cellular yield in ERαKO mice (Figure 7B). Despite the consistent decrease in BM 
SiglecH 
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Figure 7.  pDC frequency and number in the spleens and BM of WT and ERαKO 10-14 week old 
female NZM2410 mice.  Frequency and number of pDCs (B220+CD11b-SiglecH+) in spleens of NZM2410 
mice (A). Frequency and number of pDCs (B220+CD11b-SiglecH+) in the bone marrow of NZM2410 mice 
(B).  Flow cytometry plots represent data from 8 separate experiments, which are summarized in the 
graphs, WT (n=20) and ERαKO (n=17). Results are expressed as the mean ±SD. Statistical analysis 





































Figure 8. Frequency and number of cDCs in the spleens WT and ERαKO 10-14 week old female 
NZM2410 mice.  Frequency and number of cDCs (B220-SiglecH-CD11chiMHCIIhi) in spleens of NZM2410 
mice (A). Flow cytometry plots represent data from 5 separate experiments (B) which are summarized in 
the graphs, WT (n≥10 ) and ERαKO (n≥9). Results are expressed as the median ±SD. Statistical analysis 





cellularity and pDC numbers in ERαKO NZM mice, total spleen cell counts and spleen 
pDC and cDC numbers were unaltered. This finding suggests the hematopoietic 
compartment can compensate for the decreased bone marrow cellularity, perhaps by 
accelerated egress from the marrow or increased cellular life span of ERα mutant cells.  
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Figure 9.  pDC frequency and number in the spleens and BM of WT and ERαKO 10-14 week old female B6 
mice.  Frequency and number of pDCs (B220+CD11b-SiglecH+) in spleens of B6 mice (A). Frequency and number 
of pDCs (B220+CD11b-SiglecH+) in the bone marrow of B6 mice (B).  Flow cytometry plots represent data from 4 
separate experiments, which are summarized in the graphs, WT (n=7) and ERαKO (n≥5). Results are expressed 
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Figure 10. Frequency and number of cDCs in the spleens WT and ERαKO 10-14 week old female B6 mice.  
Frequency and number of cDCs (B220-SiglecH-CD11chiMHCIIhi) in spleens of B6 mice (A). Flow cytometry plots 
represent data from 4 separate experiments (B) which are summarized in the graphs, WT (n≥6 ) and ERαKO (n≥9). 





To support the hypothesis that accelerated egress of pDCs from the BM contributes to the 
equal spleen pDC numbers there was a reduction in mature Ly49Q+ pDCs in the BM of 
ERαKO NZM mice (Figure 11). Alternatively, overall pDCs in the periphery of ERαKO 
NZM mice may be decreased, but the pDCs remain in the spleen rather than migrating to 
peripheral organs impacted by disease in ERαKO mice.! 
 
 
ERα signaling did not alter the frequency of pDCs in the spleens of diseased NZM mice 
 
To determine if advanced age of the NZM mice may bring out a difference in 
pDC frequencies and numbers between WT and ERαKO mice, we measured spleen pDC 
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Figure 11. Frequency and number of Ly49Q+ pDCs in the spleens and BM of WT and ERαKO 10-14 
week old female NZM2410 mice.  Frequency and number ofLy49Q+ pDCs (B220+CD11b-SiglecH+) in 
spleens of NZM2410 mice (A). Frequency and number of Ly49Q+ pDCs (B220+CD11b-SiglecH+) in the 
bone marrow of NZM2410 mice (B).  Flow cytometry plots represent data from 8 separate experiments, 
which are summarized in the graphs, WT (n≥10 ) and ERαKO (n≥10). Results are expressed as the 








































populations in 22-26 week old, as the mice begin to develop proteinuria, WT and ERαKO 
NZM mice. We also measured the frequency of non-pDC CD11c+ cells. Similar to the 
pre-disease mice there was no change in the frequency or number of pDCs or CD11c+ 
cells in the ERαKO mice compared to WT mice (Figure 12). This finding suggests the 
effect of the mutant ERα does not impact disease by altering spleen pDC frequency or 
number.!  
 
Interestingly, there was a change in frequency and number of pDCs and CD11c+ 
cells in the spleens of the old NZM mice compared to the pre-disease NZM mice (Figure 
13) Old NZM mice have reduced pDC frequency compared to young NZM mice (Figure 
13). Additionally, the old NZM mice have an increase in frequency of CD11c+ cells 
compared to young NZM mice (Figure 13). Regarding absolute numbers, the spleens of 
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Figure 12. Frequency and number of pDCs and CD11c+ cells in the in the spleens WT and ERαKO 22-26 
week old female NZM2410.  Frequency and number of pDCs (B220+CD11b-SiglecH+) in spleens old NZM2410 
mice (22-26 wks) (A). Frequency and number of non pDC CD11c+ cells (B220-SiglecH-CD11c+) in spleens old 
NZM2410 mice (22-26 wks) (B) Flow cytometry plots represent data from 4 separate experiments (B) which are 
summarized in the graphs, WT (n≥6 ) and ERαKO (n≥8). For non normal data (pDC and cDC #), Results are 
expressed as the median ±IQR.  Statistical analysis performed with Mann-Whitney analysis. For normal data (pDC 



























old NZM mice are enlarged, therefore there is an increase in total spleen cell count. Thus, 
despite the decrease in pDC frequency there is a trend toward an increase in total number 
of pDCs in the spleens of old NZM mice. There was significantly increased number of 
CD11c+ cells in the spleens of old NZM mice compared to young NZM mice. This 



















































Figure 13. Frequency and number of pDCs and CD11c+ cells in the in the spleens of young and old female 
NZM2410.  Frequency and number of pDCs (B220+CD11b-SiglecH+) in spleens of young (10-14 weeks) and old 
(22-26 weeks) female NZM2410 mice (A). Frequency and number of non pDC CD11c+ cells (B220-SiglecH-CD11c+) 
in spleens of young (10-14 weeks) and old (22-26 weeks) NZM2410 mice (B) Flow cytometry plots represent data 
from 4 separate experiments (B) which are summarized in the graphs, young (n≥6) and old (n≥5). Results are 
expressed as the mean ±SD for % and median ±IQR for #. Statistical analysis preformed with Kruskal-Wallis test.  
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Flt3L BMDC culture:   
! BM from B6 and NZM ERαKO mice generate a reduced percent of pDCs and mDCs 
! BM from B6 ERαKO mice had increased cell yield compared to B6 WT mice 
! BM from NZM ERαKO mice had reduced cell yield compared to WT NZM mice.  
! BM cultures from NZM ERαKO mice had a greater frequency of apoptotic cells 
compared to WT NZM mice 
 
Ex vivo pDC population 
 B6 versus NZM: 
! NZM mice have increased numbers of spleen pDCs and reduced number of BM pDCs  
compared to B6 mice. This is likely due to increased pDC egress from the BM in NZM 
mice 
 
Ex vivo pDC population; NZM WT versus NZM ERαKO: 
! NZM ERαKO mice have equal number and frequency of spleen pDCs and cDCs 
compared to WT NZM mice both prior to the development of clinical disease and after 
the development of disease. 
! NZM ERαKO mice have equal frequency, but reduced absolute number of pDCs in the  






ERα signaling in Flt3L driven BMDC cultures from NZM mice 
ERα signaling impacts Flt3L driven BMDC cultures via two mechanisms. In BM 
from B6 mice, ERα signaling negatively impacts numbers of BM progenitor cells to 
reduce the total number of cells generated via this culture system [11, 51]. In the same 
cultures, ERα signaling positively impacts the maturation of late DC progenitors to 
increase the frequency of cDC and pDCs acquired from the cultures [51]. Therefore Flt3L 
driven cultures of BM from ERαKO mice yields an increased number of cells, but a 
reduced frequency of pDCs and cDCs compared to BM from ERα WT mice [11, 12]. 
Since DCs contribute to lupus pathogenesis, we wanted to determine if ERα signaling 
also impacted Flt3L driven DC development in BM from NZM lupus prone mice. 
Regarding percent of pDC and cDCs produced by cultures, we found BM from NZM 
ERαKO mice yielded reduced frequencies of pDCs and cDCs, similar to results reported 
in B6 mice and our own findings in B6 mice. This result suggests that, in lupus DCs, ERα 
signaling positively regulates the late stage of DC development. Regarding total cell 
yield, in our Flt3L of cultures of B6 BM, we found ERα signaling negatively regulated 
total cell yield, similar to previous studies [11]. However, in Flt3L cultures from NZM 
mice, ERα signaling positively impacted cell yield, indicating ERα signaling functions 
differently in DC development when cells are obtained from lupus prone animals. We 
hypothesize three possible reasons for this difference in ERα signaling between B6 and 
NZM mice; BM from lupus prone mice may have differences in the number and ratios of 
progenitor cell populations compared to B6 mice, BM cells from lupus prone mice may 
create a different cell culture environment than BM from B6 mice, or BM progenitors 
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from lupus prone mice have intrinsic genetic differences that impact ERα signaling. 
Regarding the number and ratios of progenitor cell populations, it is possible the early 
progenitor cells, which are negatively impacted by ERα signaling, may be reduced in 
lupus BM. Therefore, ERα signaling in these cultures will not negatively impact cell 
number because the ERα sensitive population of progenitors represents a smaller 
proportion of the BM population. BM cell progenitor populations have not been studied 
in lupus prone mice, therefore, it will be important to study these cell populations in the 
future. Regarding the culture environment produced by lupus BM, it is possible BM 
cultures from lupus prone mice produce an inflammatory environment due to the 
hyperactivity of lupus immune cells. Additionally, the BM cells, prior to being removed 
for culture exist in an inflammatory environment in the mouse. This environment could 
have a pre-programming effect on the BM cells, which impacts ERα signaling in 
response to Flt3L. The possibility of an inflammatory environment is important because 
ERα functions differently in DCs depending on the culture conditions [56]. ERα contains 
two activation functions, AF-1 and AF-2. The requirement for each of these domains 
various between inflammatory and steady state DC. Although AF-1 is required for steady 
state cDC development and function and early iDC development it is dispensable in 
mature iDCs [56]. Based on this evidence, ERα signaling may change in the 
inflammatory environment created in the BM of lupus prone mice.  Another possibility 
for the difference in cell yield is that BM cells and DCs from lupus prone mice have 
altered genetics, which change the way ERα signaling impacts cell development. To 
conclude, although ERα signaling functions similarly in DCs from B6 and NZM in some 
situations (later stages of DC development) ERα signaling can also have different 
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functions (early stages of DC development). Therefore we must study the role of ERα in 
both the healthy and disease state in order to understand ERα’s role in immune function 
during disease. 
 
The effect of ERα signaling on pDC populations in vivo in lupus prone mice 
 Since ERα signaling positively impacts DC generation from BM cultures from 
lupus prone mice, we hypothesized NZM ERαKO mice have fewer spleen pDCs 
compared to WT NZM mice. However, we did not detect a change in pDC or cDC 
frequency or number in the spleens of ERαKO mice compared to WT mice. This finding 
suggests ERα signaling does not impact in vivo pDC generation in the same manner as 
occurs in vitro. One possibility for the lack of change is that ERα signaling is not required 
for in vivo pDC generation.  However, Flt3L and GM-CSF are known to be critical for in 
vivo DC generation and ERα signaling impacts these pathways of DC development, 
making this scenario unlikely [51]. Another possibility is that other growth factors, 
present in vivo, compensate for the lack of ERα signaling. This possibility is likely 
because ERαKO mice have altered levels of estrogen, testosterone, and prolactin [1]. 
Changes in levels of the hormones may compensate for lack of ERα signaling therefore, 
this possibility should be further investigated. This could be done by controlling for 
hormones levels in ERαKO by ovariectomizing both WT and ERαKO mice and adding 
back physiologic levels of estradiol. Alternatively, the lack of change we reported may be 
due to an inability to detect the change caused by ERα signaling. Since we are not 
measuring total body pDCs, our findings in the spleen may be confounded by changes in 
pDC migration and distribution. Therefore, ERα’s impact may be better detected in the 
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tissue. Both GM-CSF and Flt3L are produced locally during inflammation and immune 
responses. Therefor ERα deficiency may impact cDC or pDC generation in the tissue. 
Although this explanation is likely for cDCs, as they are known to mature in the 
periphery, this is unlikely for pDCs, as they reach full maturity in the BM.  
 Since pDCs develop to maturity in the BM, we believe measuring pDCs in the 
BM is a better measure of the ability of the ERαKO mice to generate pDCs. In the BM, 
we also did not detect a change in pDC frequency in the ERαKO mice. Similar to 
possibilities in the spleen, ERα’s role in pDC generation may be unnecessary or 
compensated in vivo. Alternatively, the change in pDC frequency may be small or brief, 
therefore making it undetectable by our methods. Like in the spleen, changes in migration 
may confound our results. We hypothesized if pDCs were exiting the BM more quickly 
in WT mice, thereby negating any change in pDC frequency cause by ERα signaling, 
there would be less Ly49Q+ (mature) pDCs present in the BM of WT NZM mice 
compared to ERαKO mice. When we measured mature pDCs in the bone marrow, we did 
not see a reduction in mature pDCs in the BM of WT NZM mice. Instead, there were 
slightly less mature pDCs in the BM of the ERαKO mice. Based on our findings, we 
conclude ERα signaling does impact Flt3L driven DC generation in vitro, however, this 
effect is not detectable in vivo. Therefore, it is unlikely that ERα signaling impacts 
disease by suppressing generation of mature pDCs.   
  The ERαKO mice have a reduced number of total BM cells. One explanation for 
the reduction in total BM cellularity is that ERα signaling is required in BM 
hematopoietic progenitors for Ftl3L driven expansion. It was previously reported that 
ERα deficiency impaired the renewal of hematopoietic stem-cells in the bone marrow 
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[77]. Impairment in the expansion and renewal of early progenitors would explain a 
reduction in total BM cell count. Alternatively, ERα signaling may impact the stromal 
cell compartment. Seillet et al. showed when ERα  deficiency was restricted to 
hematopoietic cells, BM cellularity was not impacted [16]. This finding suggests the 
reduction in BM cellularity is due to changes in bone mass (reduced space for BM), or 
changes in stromal cell support of BM development. Independent of the reasoning for the 
reduction in BM cellularity, the reduced number of BM cells may contribute to disease 
protection in NZM ERαKO mice.  
 
pDC numbers in NZM2410 mice compared to B6 mice 
Two studies reported the deletion of pDCs protects lupus prone mice from 
disease, thus, confirming their importance in disease pathogenesis [9, 10]. However, 
whether they contribute to disease through abnormal numbers or function or both is not 
understood. Therefore, in order to interpret our findings in the NZM ERαKO mice we 
needed to first understand how pDC numbers are altered in NZM mice. Pre-disease 
female NZM mice have an increased frequency and number of pDCs in the spleen 
compared to age and sex matched B6 mice, indicating, changes in pDC number may 
contribute to disease. This is the first report, to our knowledge, of an increase in pDCs in 
the spleens of pre-disease lupus prone mice. In a 2013 publication, pDCs numbers were 
increased in diseased NBW F1 mice, but not in the pre-clinical disease animals [69]. The 
studies differed in stain of lupus prone mouse; however, the models are similar as mating 
the NBW F1 generation created the NZM2410 mice. The major difference between the 
studies was the method by which pDCs were identified. In Gleisner et al. CD11c and 
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B220 were used as pDC markers [69]. Using these markers there is significant 
contamination with T, B and NK cells. In our study we used CD11c B220 and the pDC 
specific marker SiglecH, which is a more accurate method of identifying pDCs [78]. 
Therefore, there is likely a true increase in pDC frequency and numbers in the spleens of 
pre-disease NZM2410 mice compared to B6 controls.  
 We also measured spleen pDC frequency and number in 22-26 week old NZM 
mice. In this old cohort the spleen pDC frequency and numbers declined to levels 
comparable to B6 mice. This finding also differs from Gleisner et al, where an increase in 
pDC frequency and number, as measured by B220, was reported in diseased mice. The 
pDC markers used could also explain the discrepancy between our findings. The marker 
we used, SiglecH, is known to decrease on pDCs in vitro when they are stimulated with 
TLR ligands (e.g. Immune complexes) [78]. Therefore, it is possible that pDCs in lupus 
animals are no longer expressing siglecH. However, the use of B220 as a sole pDC 
marker is not specific. Therefore, new models should be used to study pDCs in lupus 
prone mice. The siglecH-eGFP mouse, which expresses GFP on pDCs even if siglecH is 
down regulated, would be a good model to use in lupus [79].  
 If spleen pDC numbers are truly reduced in aged NZM mice this may be 
explained by pDCs leaving the spleen late in the course of the disease and traveling to 
sites of inflammation, which is known to occur in SLE. Alternatively, the spleen pDCs 
could convert to cDCs during the course of disease. In vitro after TLR stimulation, pDCs 
can convert to a cDC phenotype [80]. However, this conversion has not been 
demonstrated to occur in vivo. Interestingly, in this study and other publications, cDCs 
are increased in diseased mice, supporting the hypothesis DC conversion may occur. 
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Further investigation is needed to understand the fate of pDCs during the progression of 
lupus. 
 The increase in spleen pDCs in pre-diseaase NZM mice likely occurs because of 
increased migration from the BM. In our work, there was a specific reduction in mature 
pDCs in the BM of the NZM mice, suggesting NZM mice are not generating more pDCs 
than healthy mice, but rather the migration to the periphery increases in NZM mice. 
Work by Gleisner et al, supports this hypothesis, by demonstrating increased homing of 
pDCs to the spleens in lupus prone mice [69]. Based on this finding, future work should 
investigate expression of chemokine receptors on pDCs in SLE and the production of 
these chemokines in the periphery.   
 We conclude that the increased numbers of pDCs in the spleens of NZM mice 
likely contribute to disease pathogenesis. Furthermore, the increase is likely due to 
increased migration of the pDCs to the spleen. However, the NZM WT and ERαKO mice 
have equal numbers of pDCs in the spleens, indicating this is not a mechanism by which 












pDC distribution is altered in NZM mice compared to B6 mice. Furthermore, the 
frequency and number of spleen pDCs is increased in the spleen prior to the development 
of clinical disease. Based on this evidence and previous work in pDC deficient lupus 
prone mice, we conclude pDC frequency and number likely impact progression of lupus 
in NZM mice. In Flt3L driven BMDC cultures, the loss of ERα signaling negatively 
impacted the generation of mature pDC and cDC populations. Furthermore, ERα 
signaling differentially impacted Flt3L driven DC cultures from NZM mice compared to 
B6 controls. These findings suggest ERα signaling is important for DC generation, but its 
precise role varies depending on disease state. Despite the impact of ERα on in vitro DC 
generation, NZM ERαKO had no change in spleen pDC frequencies, numbers, and 
maturation state compared to WT NZM mice, suggesting in vivo DC generation 
compensates for a lack of functional ERα signaling. Interestingly, the total BM cell count 
was reduced in ERαKO mice compared to WT mice. Since this decrease was not specific 
to the pDC lineage, this finding suggests functional ERα signaling may be required for 
hematopoietic progenitor cell survival. Since the progenitor cells are responsive to Flt3L, 
this finding may represent an in vivo role of ERα in Flt3L signaling. Additionally, the 










Diagram 7  
Aim I Summary 
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ERα signaling increased BM cell counts in pre-disease NZM mice 
! 50!
2.6 Future Directions 
 
The findings presented in this chapter suggest the NZM ERαKO mice are not 
protected from disease by having impaired generation of pDCs. However, we have shown 
that pDC number is altered in pre-disease mice, suggesting pDC distribution and number 
impact pathogenesis. Additionally, we have shown in vitro ERα signaling is important for 
pDC generation. The reason why ERα impacts FLt3L driven in vitro culture of DCs but 
does not impact in vivo generation of these cells remains unanswered. The difference 
could be due to changes in hormone levels in ERαKO mice. The ERαKO mice have 
increased levels or estrogen and testosterone compared to WT mice. Additionally, in the 
ERαKO model small amounts of mutant ERα protein lacking only the AF1 domain are 
produced. Since AF1 function is dispensable for different stages of DC development, the 
high levels of estradiol in the ERαKO mice may drive the function of the mutant ERα 
thereby impacting in vivo pDC development and explain the discrepancy (since estradiol 
levels are low in the culture conditions).  
 Although we did not see a difference in pDC populations specifically, we did see 
a reduction in total BM cellularity in the ERαKO mice. To determine if this is a change 
caused by ERα in the hematopoietic or stromal cell compartment we should study 
ERαKO in a DC specific model. Although a BM transplant could be used to study this 
effect in B6 mice, the NZM2410 mice a radiation resistant. Additionally, the use of AF1 
and AF2 ERα mutants would also be helpful in understanding ERα’s role in disease.  
 Regarding the role of pDCs in lupus, independent of ERα, much work is needed 
to understand the function of these cells during disease. Three areas of potential interest 
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have been identified in this study. First, the migration pattern of pDCs is not understood 
in lupus. Second, BM composition has not been investigated in lupus prone mice, and our 
work suggests changes occur in this compartment prior to clinical disease. Third, the fate 
of pDCs throughout the course of disease should be studied. Specifically,  the idea of 












































Chapter 3: Impact of estrogen receptor 




















Chapter 3 Impact of Estrogen Receptor α on plasmacytoid dendritic cell activation 
 
3.1 Introduction 
pDC activation and function 
 pDCs share a precursor and name with cDCs, but they function differently than 
cDCs. In mice, pDCs express only the endosomal TLRs 7 and 9 [38].  Once either TLR is 
stimulated, typically in response to 
viral infection, pDC produce large 
amounts of type I IFNs. The type I 
IFN produced by pDCs function to 
activate T, B, NK cells, and other 
DCs. Alternatively, pDCs can also 
express high levels of MHCII, 
costimulatory molecules, and 
produce TNF and Il-16 in response 
to TLR stimulation [37]. 
Expression of MHCII, 
costimulatory molecules and 
production of TNF and Il-6 allow 
pDCs to act to acquire T 
stimulatory capacity [81].  
 
TLR7 and TLR9 sense ssRNA and unmethylated CpG containing DNA, 
respectively.  TLR9 can be stimulated by different types of CpG, included CpG type A 
Diagram 8 TLR signaling in plasmacytoid 
dendritic cells 
Gilliet, 2008 
TLR 7 and 9 ligands induce IFNα, IL-6,  and TNF 
production and expression of costimulatory 
molecules in pDCs 
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and type B. Type A is a multimeric structure, which preferentially induces IFN 
production and CpG type B is a monomeric structure, which induces T cell stimulatory 
capacity [44]. Once stimulated both TLR7 and 9 recruit the adaptor molecule MyD88. If 
CpG A is the stimulus MyD88 recruitment results in a signaling cascade leading to the 
phosphorylation and nuclear transport of IRF7 and type I IFN transcription (Scheme 5) 
[44]. If CpG B stimulates TLR9 MyD88 will recruit a different set of signaling 
molecules, which results in NFkB activation, which promotes T cell stimulatory capacity 
(Scheme5) [44].  
Regulators of pDC type I IFN production are known. These include IRF7, PI3K, 
Ly49Q, and PDC-TREM. The constitutive expression of IRF7 contributes to the pDC’s 
ability to quickly produce large amounts of IFNs. PI3K activation of mTOR positively 
regulates IFN production by promoting the nuclear localization of IRF7 [82]. Two 
markers of pDC activation, specific to the IFN pathway are Ly49Q and PDC-TREM. 
Ly49Q expression is acquired by pDCs as a late stage maturation marker in the bone 
marrow and is required for IFN production [73, 74, 83]. PDC-TREM expression is 
acquired after TLR stimulation and is also required for IFN production [84]. PDC-TREM 
is associated with the cellular signaling molecule DAP12, which functions as an 
activating moiety when associated with PDC-TREM, that phosphorylates PI3K and 
ERK1/2 upon stimulation of pDC-TREM [84]. Stimulation of SiglecH and BST2 down 
regulate the IFN response [37]. Interestingly, SiglecH also signals through DAP12, 
however, in this case DAP12 acts as an inhibitory molecule [78]. 
Regarding antigen presentation, pDCs can express high levels of MHCII and 
present antigen to stimulate T cells after TLR engagement. pDC antigen presentation 
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differs from cDC antigen presentation because pDCs require TLR stimulation to present 
antigen. Additionally, pDCs continuously synthesize MHCII so that they are able to 
constantly sample the environment and present new antigen [85]. There is in vitro 
evidence that pDCs, once stimulated by TLR ligands, convert completely to a cDC 
phenotype [37]. However, there is no evidence to support this occurs in vivo or in lupus 
[37].   
 
DC activation and lupus 
In SLE, there are increased levels of type I IFNs and inflammatory cytokines. The 
increase in IFN levels is due to an inappropriate stimulation of pDC TLRs by immune 
complexes [44]. Immune complexes from SLE patients induced type I IFN production 
from pDCs. Additionally, when pDCs are deleted from lupus prone mice, IFN activity is 
reduced and mice are protected from disease[10]. However, the specifics of pDC activity 
during human and murine disease are not well understood. Lupus pDCs display an altered 
activation status. In mice, lupus mDCs and pDCs express increased levels of CD40 and 
reduced CD54 and CD80 compared to normal controls [70]. Furthermore, mDCs express 
high levels of CD40 prior to the development of clinical disease [70]. Human monocyte-
derived DCs from SLE patients express higher levels of HLA-DR and the co-stimulatory 
molecules CD86 and CD80 [86, 87]. As a result, SLE mDCs also induce T cell 
hyperactivity [88]. pDCs from SLE patients were found to have normal levels of 
costimulatory molecules [41]. When SLE pDCs were stimulated ex vivo with CpG, pDCs 
from SLE patients produced less type I IFN compared to controls [89]. The reduced IFN 
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production was attributed to over stimulation with TLR ligands in SLE. Thus, more work 
should be done to understand the activity levels of mDCs and pDCs in SLE.  
 
  
Dendritic cells and ERα 
 ERα signaling also impacts DC activation and function. ERα signaling promotes 
the function of pDCs and mDCs (see introduction). Regarding pDC IFN production, ERα 
signaling increased pDC production of IFNα in response to TLR 9 stimulation [16]. The 
increase in type I IFN production occurred when estradiol was given in vivo to humans 
and mice and when it was given at the time of ex vivo TLR stimulation [16, 53]. When 
mice were given estradiol in vivo prior to ex vivo TLR stimulation, the increase in IFNα 
production was dependent on ERα signaling [16]. In these studies only the in vitro 
stimulation of pDC activity was studied, therefore work should be done to address ERα’s 
role in pDC activation in vivo. Additionally, ERα’s impact on DC activity in SLE should 














pDC activity impacts lupus pathogenesis. Additionally, ERα signaling positively impacts 
pDC activity. However, the connection between pDC activation, ERα, and lupus 
pathogenesis has not been explored. We hypothesized ERα signaling positively 
regulates pDC activation in pre-disease NZM2410 lupus prone mice. ERα’s role in 





















Diagram 9  
Aim II Hypothesis 
We hypoethesize ERα signaling increases pDC activation in lupus prone mice 
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3.3 Results 
Absence of functional ERα reduced the frequency of activated spleen pDCs in NZM2410 
mice.  
 
 Since the absence of functional ERα did not alter spleen pDC percent or number, 
but does have a significant effect on disease expression, we hypothesized the lack of 
functional ERα impairs the activation of pDCs in NZM mice. To determine the effect of 
ERα signaling on the activation state of DCs in NZM mice, we measured the frequency 
of pDCs and cDCs expressing major histocompatibility complex class II (MHCII) and 
CD40, two described markers of DC activation. MHCII expression is required for antigen 
presentation and CD40 expression is necessary for T cell activation [85, 90].  
Additionally, in Sle1,2,3 mice, cDCs have increased CD40 expression prior to disease 
WT!
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Figure 14. Frequency of 
activated spleen pDCs 
and cDCs. Frequency of 
MHCII+ (A) and CD40+ 
(C) pDCs and median 
f luorescent in tensi ty 
(MFI) of pDC MHCII (A) 
and CD40 (C) in the 
spleens of WT (n=13) 
and ERαKO (n=10 ) 
10-14 week old female 
NZM2410 mice in 5 
separate experiments. 
Frequency of MHCII+ (B) 
and CD40+ (D) cDCs and 
MFI of cDC MHCII (B) 
and CD40 (D) in the 
spleens of WT (n=7) and 
ERαKO (n=8) 10-14 
w e e k  o l d  f e m a l e 
NZM2410 mice in 3 
separate experiments. 
Gates for frequency were 
set in each experiment 
based on a fluorescence 
m i n u s o n e ( F M O ) 
control . Resul ts are 
expressed as the mean 
±SD or median± IQR . 
S t a t i s t i c a l a n a l y s i s 
performed with student’s 
T test or Mann-Whitney 
analysis.  Based on 



























[70]. As shown in Figures 14A and C, the absence of functional ERα reduced the 
frequency of pDCs expressing MHCII, but not CD40. ERα genotype did not alter the 
frequency of cDCs expressing MHCII or CD40  (Figure 14B and 14D). The reduced 
frequency of MHCII+ pDCs was restricted to the NZM mice, as MHCII expression on 
pDCs from B6 mice was not altered by the functional deficiency of ERα (Figure 15).  
These findings suggest ERα specifically impacts pDC activation during disease.!
  
NZM mice have reduced DC MHCII expression compared to B6 control mice 
 
Since ERα altered the frequency of MHCII+ pDC in NZM mice, we compared 
MHCII expression in NZM mice to B6 mice to understand how disease impacts DC 
MHC II expression. Independent of ERα, there was a reduced frequency of MHCII+ 
pDCs in NZM mice compared to B6 controls (Figure 15).  We also detected an increased 
frequency of MHCII+ cDCs in NZM mice compared to B6 controls (Figure 16). 
However, there was a reduced intensity of the MHCII staining in NZM mice compared to 
B6 mice (Figure 16). Thus, there is a greater frequency of MCHII + cDCs in NZM mice. 










B6 pDC: % MHCII+
Figure 15 
Figure 15. Frequency of activated spleen pDCs in B6 mice. Frequency of MHCII+ pDCs (A) in 
the spleens of WT (n=9) and ERαKO (n=12) 10-14 week old female B6 mice in 4 separate 
experiments. Gates for frequency were set in each experiment based on a fluorescence minus 
one (FMO) control. Results are expressed as the mean ±SD. Statistical analysis performed with 
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However, each cDC expresses less of the MHCII molecule. This finding suggests that 
NZM cDCs may be down regulating MHCII as either a negative feedback mechanism or 
as part of disease pathogenesis.!   
 
 
Absence of functional ERα does not alter the maturation state of pDCs in NZM2410 
mice.   
 
Since ERα impacts cell number in the bone marrow and is known to alter DC 
development in vitro, we wanted to ensure the pDCs from ERαKO mice reached 
maturity, as lack of full maturity may explain an impaired ability to activate. We 
measured the expression of Ly49Q on the spleen pDC population as a marker of pDC 
maturation. Ly49Q is only expressed on fully mature pDCs and denotes their ability to 
respond to TLR stimuli and produce IFNα [73, 74, 83]. In B6 mice, the majority of 
spleen pDCs express this marker. The majority of spleen pDCs from NZM female mice 
also expressed Ly49Q and ERα deficiency did not alter the frequency or absolute number 
Figure 16 
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Figure 16. Frequency of activated spleen cDCs in B6 and NZM mice. Frequency of 
MHCII+ cDCs (A) and the MFI of MHCII+ cDCs (B) in the spleens of B6 WT (n=9) and 
NZM WT  (n=13) 10-14 week old female mice in ≥ 4 separate experiments. 
Representative flow cytometry plot (C) Gates for frequency were set in each experiment 
based on a fluorescence minus one (FMO) control. Results are expressed as the mean 
±SD. Statistical analysis performed with a student’s T test analysis.   
 





of pDCs expressing Ly49Q (Figure 17). ERα deficiency thus does not alter the 




Absence of functional ERα reduced the frequency of PDC-TREM+ pDCs in NZM2410 
mice.   
 
Since the reduced frequency of MHCII+ pDCs was not detected in B6 mice, we 
hypothesized the ERα modulates pDC response to inflammatory stimuli present in 
disease, such as TLR 7 or 9 ligands. In lupus, self-nucleic acids in immune complexes 
stimulate TLR7 and 9 in pDCs [91]. TLR signaling results in the activation of pDCs. 
Although we studied mice pre development of autoantibodies and renal disease, it is 
likely some immune abnormalities are present in the preclinical state of disease. To 
determine if altered TLR signaling may be responsible for the reduction in pDC MHCII 
expression, we measured the expression of the early pDC activation marker PDC-TREM. 
PDC-TREM is expressed on pDCs preferentially after exposure to TLR ligands and type 
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Figure 17. Frequency of Ly49Q+  spleen pDCs. Frequency of Ly49Q+ pDCs and MFI of Ly49Q on 
pDCs in the spleens of WT (n=10) and ERαKO (n=10) 10-14 week old female NZM2410 mice in 4 
separate experiments Results are expressed as the mean ±SD. Statistical analysis performed with a 






I IFNs [84]. Absence of functional ERα significantly and reproducibly reduced the 
frequency of PDC-TREM+ pDCs in the spleens of NZM mice in vivo (Figure 18). pDCs 
from NZM mice also had reduced MFI of PDC-TREM. This reduction was also specific 
to the NZM mice, as it was not detected in pDCs from ERαKO B6 mice (Figure 19). The 
percent of splenic pDCs expressing PDC-TREM was significantly higher in the WT 
NZM mice versus B6 mice suggesting heightened pDC activity in lupus prone mice even 
at the preclinical disease stage (Figure 20). This finding suggests the alteration in pDC 
activation state may be due to an impaired response to TLR ligands in vivo in ERαKO 
pDCs from NZM mice.  
We also measured PDC-TREM expression on pDC from 22-26 week old female 
WT and ERαKO NZM mice. Like, the pre-disease mice the ERαKO had a reduced 
















Figure 18. Frequency of PDC-TREM+ spleen pDCs. Frequency of PDC-TREM+ pDCs and MFI of 
PDC-TREM on pDCs in the spleens of WT (n=13) and ERαKO (n=9) 10-14 week old female NZM2410 
mice in 6 separate experiments (A). Frequency of PDC-TREM+ pDCs and MFI of PDC-TREM on pDCs 
in the spleens of WT (n=7) and ERαKO (n=8) 22-26 week old female NZM2410 mice in 3 separate 
experiments (B) Results are expressed as the mean ±SD (A) or median ±IQR. Statistical analysis 
performed with a t-test analysis (A) or Mann-Whitney analysis (B) 
 






















































frequency of PDC-TREM+ pDCs compared to WT pDCs (Figure 20). We did not see any 
changes in PDC-TREM+ pDC frequency with advanced age, suggesting this change in 




Figure 19. Frequency of PDC-TREM+ pDCs in the spleens B6 mice. Frequency of PDC-TREM+ 
pDCs  and MFI of PDC-TREM on pDC in the spleens of WT (n=9) and ERαKO (n=12) 10-14 week old 
female B6 mice in 4 separate experiments. Gates for frequency were set in each experiment based on 
a fluorescence minus one (FMO) control. Results are expressed as the mean ±SD. Statistical analysis 
performed with a Student’s T Test.   
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Figure 20. Frequency of PDC-TREM+ pDCs in the spleens of 
B6 and NZM mice. Frequency of PDC-TREM+ pDCs in the 
spleens of B6 WT (n=9) and NZM WT  (n=13) 10-14 week old 
female mice in ≥ 4 separate experiments. Gates for frequency 
were set in each experiment based on a fluorescence minus one 
(FMO) control. Results are expressed as the mean ±SD. Statistical 
analysis performed with a Student’s T test.   
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IFN signature is reduced in ERαKO NZM mice prior to clinical disease 
 
PDC-TREM expression is required for pDCs to produce type I IFNs. Since ERα 
modulates PDC-TREM expression, we hypothesized it also impacts type I IFN activity in 
lupus prone mice. To assess type I IFN activity, we measured expression of type I IFN 
responsive/signature genes in the whole spleens of NZM mice. We measured genes that 
are elevated in BM derived DCs of pre-disease lupus-prone mice compared to B6 mice 
[47]. Using this previously validated assay, we found the absence of ERα significantly 
reduced the expression of the Type I IFN signature genes Cxcl-10 and Mx1 (Figure 21).  
There was a trend towards reduced Isg-15, and Irf-7 expression (Figure 21).! There were 
no detectable levels of IFNα or IFNβ, which can be attributed to the relative scarcity of 
pDCs and cDCs in the spleen. Furthermore there was an increase in Isg-15 expression in 
Figure 21 
Figure 21. Expression 
o f I F N s i g n a t u r e 
genes in spleens of 
pre-disease  NZM WT 
and ERαKO mice 
Expression of Cxcl10, 
Mx1, Isg15, and Irf7 in 
spleens of WT (n=10) 
and ERαKO (n=13) 
10-14 week old female 
NZM mice in ≥ 4 
separate experiments. 
F o l d c h a n g e w a s 
calculated compared to 
13 week old female B6 
mouse. Results are 
e x p r e s s e d a s t h e 
m e d i a n  ± I Q R . 
Stat ist ical analysis 
p e r f o r m e d  w i t h 
K r u s k a l - W a l l i s 
analysis.   
 





























































NZM compared to B6 controls, suggesting IFN activity is increased in NZM mice 
compared to B6 controls. This finding demonstrated that ERα deficiency reduced type I 
IFN activity in pre-clinical disease NZM mice.  We believe that the inflammatory state of 
NZM female mice, even prior to clinical disease, leads to detectable differences in pDC 
activation due to a key role of ERα in TLR/IFNα mediated inflammation. It is important 
to note, we did not detect an increase in all IFN signature gene expressions in the spleens 
from NZM mice compared to B6 controls. We chose these genes because they are 
increased in BMDCs from SLE1,2,3 mice compared to B6, however, they are not 
Figure 22 
Figure 22. Expression of IFN signature genes 
in spleens of diseased  NZM WT and ERαKO 
mice Expression of Cxcl10, Mx1, Isg15, Irf7, IFNγ 
in spleens of WT (n=10) and ERαKO (n=13) 
22-26 week old female NZM mice in ≥ 4 separate 
experiments. Fold change was calculated 
compared to 13 week old female B6 mouse. 
Results are expressed as the median ±IQR. 
Statistical analysis performed with Kruskal-Wallis 
analysis.   
 









































































consistently increased in ex vivo isolated spleen cells [47]. This is likely due to the 
heterogeneity of the spleen cells.!
 
We also wanted to determine if advanced disease could expand the difference in 
IFN signature gene expression between WT and ERαKO NZM mice, therefore we 
measured the expression of the IFN signature genes in a 22-26 week old cohort of WT 
and ERαKO NZM mice. In these mice we did not see a significant change in any genes. 
Furthermore, there was a trend towards increased levels of mx1 and irf-7 in the spleens of 
NZM ERαKO mice compared to WT controls (Figure 22). The lack of change between 
IFN signature genes in the aged group of mice may be due to the immunological changes 
occurring from the disease process.  Additionally, we measured IFNγ expression in the 
spleen, as this may contribute to IFN signature gene expression, thus accounting for 
differences between genotype. However, IFNγ does not likely contribute to the IFN 
signature as levels were not reduced in the spleens ERαKO compared to WT.! 
To strengthen our evidence for ERα impacting type I IFN activity in NZM mice, 
we chose to measure Sca-1 expression on spleen T and B cells, which is a measure of 
Figure 23 
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Figure 23. Frequency 
of Sca-1+ T and B 
cells in the spleen of 
NZM WT and ERαKO 
mice Frequency of 
Sca-1+ T cells DCs (A) 
and Sca-1+ B cells (B) 
in the spleens of WT 
(n=11) and ERαKO 
(n=8) 10-26 week old 
female mice in ≥ 4 
separate experiments. 
Representative flow 
cytometry plot (C). 
Results are expressed 
as the mean ±SD. 
Stat ist ical analysis 
p e r f o r m e d  w i t h 









chronic type I IFN exposure. We did not detect any difference in the frequency of B or T 
cells expression SCA-1 nor did we detect a change in MFI between the ERα genotypes 
(Figure 23). We performed this test in both old (22-26 week old) NZM and young (12-14 
week old) NZM mice. The lack of change could be attributed to a low sensitivity to 
detect a subtle change caused by the deficiency of functional ERα.  
We also measured IFN signature genes in the kidneys of diseased (22-26) week 
old NZM2410 mice. We found that 1 of the WT mice had highly increased levels of the 
IFN signature genes, suggesting ERα signaling plays a role in kidney IFN activity (Figure 
24). This experiment was preformed only once because we could not detect pDCs in the 
kidneys of NZM mice, however, kidney endothelial cells may contribute to this IFN 
signature and thus could 
be explored further [92].! 
 
We measured IFN 
signature in total spleen 
cells after 18 hours of 
TLR9 stimulation. We 
preformed this test to 
study the IFN signature 
producing capacity of the 
spleen DCs. Using this 
method we did not detect a 
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Figure 24 
Figure 24. Expression of IFN signature genes in 
the kidneys  of NZM WT and ERαKO mice 
Expression of Cxcl10, Mx1, Isg15, and Irf7 in spleens 
of WT (n=) and ERαKO (n=2) 22-26 week old female 
NZM mice 1 experiment.  
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signature gene expression between genotypes (Figure 25).  
Since PDC-TREM expression is consistently reduced in pDCs from ERαKO mice 
and PDC-TREM is an important regulator of pDC type I IFNα production, it is likely our 
measures of type I IFN activity were not sensitive enough to detect large change between 
genotypes. However, we did detect a reduction in two of the four IFN signature genes 
measured in the spleens of pre-disease NZM2410 mice, suggesting IFN activity is 
reduced in ERαKO mice. This reduction in IFN activity may contribute to reduced 
























Figure 25. Expression of IFN 
signature genes in TLR9 
stimulated spleens of NZM 
W T a n d E RαK O m i c e 
Expression of Ifna, Ifnb, 
Cxcl10, Mx1, Isg15, and Irf7 in 
spleens cells of WT (n=5) and 
ERαKO (n=5) 10-14 week old 
female NZM mice after 18 
hours of TLR 9 sitmulation in ≥ 
3 separate exper iments. 
Results are expressed as the 
mean ±SD. Statistical analysis 
performed with Kruskal-Wallis 




Ex vivo activation status 
! Pre-disease NZM ERαKO mice have a reduced frequency of pDCs  
 expressing MHCII and PDC-TREM compared to WT NZM mice 
! NZM mice have an increased frequency of PDC-TREM expressing pDCs  
 compared to B6 
! In B6 mice, ERαKO does not alter PDC activation status 
! Pre-disease NZM ERαKO have reduced expression of IFN signature genes in  

















In pre-disease lupus prone NZM2410 mice, the functional mutant of ERα reduced 
pDC activation phenotype in vivo without impacting pDC number or maturation. 
Specifically, the functional mutant of ERα reduced pDC expression of PDC-TREM, a 
modulator of pDC type I IFN production. The absence of functional ERα simultaneously 
reduced type I IFN activity in the spleens of the pre-disease NZM mice. Given the key 
role of pDCs and type I IFNs in murine models of lupus, these findings suggest that 
ERα’s ability to modulate pDC activation and type I IFN activity is a mechanism by 
which the functional mutation of ERα  protects NZM mice from disease. 
DCs from lupus patients and lupus prone mice have altered expression of 
activation markers [70, 87, 93]. Our study is unique in measuring the effect of ERα  
signaling on the in vivo pDC activation state in lupus prone mice without ex vivo 
stimulation of the pDCs. We have identified changes in pDC activation state induced by 
the absence of functional ERα signaling in NZM mice prior to the development of 
clinical disease, therefore, our findings may represent a mechanism by which ERα 
functional mutation protects NZM mice from disease rather than reflecting an effect of 
differential disease severity. Other studies have previously reported the impact of 
estrogen/ERα on DC activation after stimulation with TLR ligands. Our data is in 
agreement with Douin-Echinard et al. which showed that ERα  deficiency reduced TLR9 
mediated MHCII expression without altering CD40 expression in BMDCs cultured from 
B6 mice [12]. Alternatively, in Li et al. the addition of estradiol at the time of TLR9 
stimulation increased pDC CD40 expression, suggesting estrogen differentially affects 
DC activation phenotype depending on whether the estrogen exposure/signaling is short 
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(in vitro addition of estrogen) or long-term (in vivo deficiency of ERα ) [53]. The long-
term deficiency of ERα  signaling, both in our study and Douin-Echinard et al. 
demonstrated a specific impact on pDC MHCII expression in ERα functionally deficient 
cells [12]. Furthermore, the functional mutation of ERα reduced MHCII expression on 
spleen pDCs from NZM mice, but not spleen pDCs from B6 controls. Therefore, ERα ’s 
role in pDC activation phenotype in vivo appears either strain specific or represents an 
effect of early disease in the NZM mice. One reason for this specificity could be that 
ERα  modulates pDC activation in response to immune stimuli present uniquely in NZM 
mice (e.g. TLR7/9 ligands) [94]. Alternatively, a pDC intrinsic/genetic factor specific to 
NZM mice could mediate ERα’s effect . We believe the former mechanism is most likely 
given that, after in vitro TLR stimulation, ERα  signaling also increased expression of 
MHCII on pDCs from both NZM and B6 mice. These results suggest ERα’s  effect on the 
pDC activation phenotype, in response to TLR stimulation is independent of the pDC 
strain background. In this study we have both confirmed that the functional mutation of 
ERα impaired pDC activation phenotype and the reduction this occured in pDCs of NZM 
mice prior to development of clinical disease. These findings indicate pDC abnormalities 
in NZM2410 mice are an early marker of disease, which are impacted by ERα 
expression.  
A novel finding of our results is that the functional mutation of ERα reduced 
PDC-TREM expression on spleen pDCs from pre-disease NZM mice. To our knowledge, 
this is the first report of an effect of estrogen and/or ERα on PDC-TREM expression. 
pDCs acquire PDC-TREM protein on the cell surface upon TLR stimulation and this 
surface expression is required for pDCs to produce IFNα [84]. The reduction in PDC-
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TREM expression on pDCs from ERαKO NZM mice suggests that the absence of 
functional ERα impairs activation in response to TLR signaling in vivo. Wataria et al. 
showed that TLR7 and TLR9 ligands induced PDC-TREM expression and IFNα, TLR4 
ligand, and PolyA stimulation alone could not induce PDC-TREM expression [84]. Since 
TLR7/9 stimuli are known to be present in WT and ERαKO NZM mice (immune 
complexes), but less so in B6 mice, in vivo pDC expression of PDC-TREM is likely 
mediated, at least partially, by TLR signaling [1]. However, Swiecki et al. showed that 
MyD88 was not required for PDC-TREM expression during HSV-1 infection, suggesting 
stimuli other than the MyD88 dependent TLR7 and 9 ligands can induce PDC-TREM 
expression [79]. Therefore ERα may alter PDC-TREM expression via another pDC 
activation pathway, such as NOD-like receptors or RIG-I-like receptor stimulation or 
more specific modulators of pDC activity, such as Ly49Q or SiglecH signaling in vivo.  
The reduction in PDC-TREM expression on pDCs from NZM mice also suggests 
ERα modulates the pDC type I IFN production pathway. This idea is supported by the 
reduction in spleen type I IFN activity in NZM ERαKO mice. Our findings are in 
agreement with Seillet et al., who showed that estradiol via ERα enhanced pDC IFN 
production [16]. In Seillet et al., the deficiency of ERα prevented the estrogen mediated 
pre-programming of pDCs in vivo, thereby reducing pDC IFN production in response to 
TLR stimulation [16]. Our findings demonstrate a possible effector molecule through 
which ERα modulates pDC type I IFN production. Like MHCII expression, the 
functional mutation of ERα reduced PDC-TREM expression on pDCs from cultured 
BMDCs after in vitro TLR stimulation in both BMDCs from NZM and B6 mice. Since, 
after in vitro TLR stimulation, ERα deficiency impacts PDC-TREM expression in both 
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strains of mice, these data suggest ERα modulation of PDC-TREM may represent both a 
mechanism of disease protection and a general mechanism by which ERα impacts type I 
IFN production and TLR responses.  
 
To accurately measure type I IFN activity in lupus prone mice, without artificially 
stimulating the cells, we measured the expression of type I IFN signature genes in the 
spleen. The genes measured are elevated in BMDCs and certain splenocytes of pre-
disease Sle-1,2,3 mice compared to B6 mice [47].  Expression of these genes represents 
the cellular response to type I IFN stimulation, thereby the assay measures both the 
amount of functional type I IFN present in an environment and the ability of the affected 
cell to respond to type I IFN. We measured the IFN signature genes in total spleen cells, 
thus we measured the responsiveness of total spleen to type IFN. As previously 
published, IFN signature gene expression varies between spleen cell type, thus, this 
variation likely impaired our ability to detect dramatic changes in IFN signature gene 
levels. However, we did detect significant change in 2 of the 4 genes measured, 
suggesting Erα signaling positively impacts the cycle of type I IFN production and 
response. Based on the mechanics of the assay, ERα may alter the amount of type I IFN 
produced, the responsiveness of spleen cells to the IFN, or both.  
 We hypothesized the difference in IFN signature gene expression between 
genotypes would widen as diseased progressed. However, the difference between the 
genotypes was reduced in diseased NZM mice. This finding may be due to immune 
abnormalities occurring as disease progresses or ERα signaling impacting a negative 
feedback loop. There was a trend towards increased ISG-15 in the spleens of the 22-26 
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week of NZM ERαKO mice compared to NZM WT mice. ISG-15 protein is a ubiquitin 
like protein that covalently attaches to target proteins [95]. Once attached ISG-15 can 
regulate protein function and survival. Thus, it may be possible increased levels of ISG-
15 in the ERαKO negatively regulates type I IFN production as disease progresses.  
Other studies have shown estrogen via ERα  affects pDC production of type I IFN 
[16, 53]. In Seillet et al., the treatment of post menopausal women with estradiol in vivo 
induced pDCs to produce higher amounts of IFNα upon TLR stimulation [16]. Further 
more, Seillet et al. showed that estradiol’s impact on IFNα production was dependent on 
ERα in mice. Li et al. demonstrated that simultaneous in vitro estradiol and TLR 
treatment enhanced pDC type I IFN production compared to TLR stimulation alone [53]. 
Although these papers argue that estradiol/ERα alters pDC IFN production through 
different mechanisms, they both agree that estradiol/ERα positively impacts type I IFN 
production, which may explain our findings. Although these studies address similar 
questions as our work, they differ in that they focus strictly on pDC production of type I 
IFNs in response to acute exposure to TLR ligand. Since the IFN signature gene 
expression measures total type I IFN activity in a given environment, our data represents 
type I IFNs produced by pDCs in response to endogenous stimuli present in the spleens 
of lupus prone mice. This is an important differentiation, as TLR stimulation does not 
fully account for the IFN signature seen in lupus prone mice [47]. Alternatively, a 
different cell type could produce the IFN. Although pDCs are typically the major source 
of type I IFN, viral infection can induce cDCs to produce significant amounts of type I 
IFN [96]. Therefore, in the future, both pDC and cDC type I IFN production should also 




In pre-disease NZM2410 mice, ERα signaling positively impacted pDC activation 
state. Since this finding is restricted to NZM2410 mice and not seen in B6 mice, ERα 
signaling likely impacted pDC activation in response to disease specific stimuli. 
Furthermore, ERα signaling positively impacted pDC expression of PDC-TREM, a 
regulator of pDC IFNα production. ERα also positively impacted endogenous IFN 
activity in NZM mice prior to the development of clinical disease. These findings suggest 
ERα signaling may alter the IFN production pathway by influencing expression of PDC-
TREM. Since type I IFNs are critical in lupus pathogenesis, we believe ERα’s impact on 
pDC and IFN activity may represent a mechanism by which the functional mutation of 
ERα protects mice from disease. Additionally, we found these changes prior to the 
development of clinical disease, which further supports the hypothesis that these changes 
















Diagram 10  
Aim II Summary 
ERα signaling increased endogenous pDC activation in pre-disease lupus prone mice 
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3.6 Future Directions 
Future work could address ERα’s role on in vivo type I IFN production. Although 
we detected a change in total spleen IFN signature gene expression in the NZM ERαKO 
mice we did not identify the cells producing IFN nor did we identify the cells affected by 
IFN. To answer these questions we could sort pDCs and cDCs from WT and ERαKO 
NZM mice. Then IFNα and IFNβ transcripts could be measured both with and without 
exogenous TLR stimulation. This would determine if ERα regulates pDC IFN production 
in vivo. Additionally, we can sort B, T and NK cells from the spleen and measure their 
expression of IFN signature genes to determine if ERα signaling impacts their response to 
endogenous IFN activity.  
 We looked for pDCs in the kidneys in NZM mice. However, were not able to 
detect these cells by flow cytometry. Other groups have reported a lack of kidney pDCs 
in mice, however pDCs are present in the kidneys in humans with SLE [79]. 
Additionally, we detected highly increased expression of IFN signatures genes in 1 WT 
NZM mouse, but not the 2 ERαKO mice. Therefore it may be worthwhile to look into 
pDCs and type I IFNs in the kidneys of WT and ERαKO NZM mice. Since resident 
kidney cells produce type I IFNs in lupus, ERα may regulate kidney resident cell 
production of IFN [92]. Alternatively, it is possible that pDCs infiltrate the kidney and 
murine lupus, but lose traditional pDC markers. pDC markers can be lost in vitro after 
TLR stimulation [78]. Thus, a lupus mouse model with a fluorescently tagged pDCs may 
help determine the fate of pDCs as disease progresses. Lastly, ERα may regulate cDC 
production of type I IFNs in the kidneys.  cDCs are found in lupus kidneys and cDCs 
have been shown to be able to produce large amounts of type I IFNs under inflammatory 
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conditions [Cunningham, unpublished data] [96]. Therefore, IFN production by kidney 

































Chapter 4:  The impact of estrogen 













Chapter 4:  The impact of estrogen receptor α signaling on PDC-TREM expression 
 
4.1 Introduction 
Pre-disease ERαKO NZM mice have a reduced frequency of PDC-TREM+ pDCs 
compared to WT NZM mice. PDC-TREM regulates pDC IFN production, thus, likely 
impacts disease activity in NZM mice. In this chapter, we will explore the mechanisms 
by which ERα signaling mediates expression of PDC-TREM.  
 
PDC-TREM 
 TREM, triggering receptor expressed on myeloid cells, proteins are a family of 
surface receptors that function to modulate cellular responses on myeloid cells [97]. 
TREM proteins are expressed on dendritic cells, macrophages, osteoclasts, microglia, 
monocytes, and platelets [97]. Both human and mouse cells express TREMs [97]. In 
mice, TREMs 1-4 have been identified and in humans TREM proteins 1 and 2 have been 
identified, however, a genomic region with similarities to mouse TREM 3 and 4 are 
present [97]. TREMs function to integrate cell signals and regulate cell responses through 
both inhibitory and activating mechanisms [97]. TREMs signal through the adaptor 
molecule DAP12, which may contain either an ITAM or ITIM, with activating or 
inhibiting functions, respectively [97] 
 PDC-TREM, also known as TREM-4, is the most recently described TREM 
protein in mice [97]. It is expressed exclusively on pDCs and is expressed after TLR 
stimulation [84]. It is not detected on naive pDC. Its surface expression, in response to 
TLR stimulation, is dependent on MyD88, IFNAR, and DAP12 [84]. Once expressed on 
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the cell surface PDC-TREM associates with PlexinA1 and the intracellular adaptor 
molecule DAP12, which contains an ITAM (activation) signaling domain [84]. Although 
MyD88 is required for PDC-TREM expression induced by TLR stimulation, during 
HSV1 infection PDC-TREM is expressed independent of MyD88, suggesting non-
MyD88 dependent stimuli may contribute to its surface expression [79]. Although little is 
known about PDC-TREM ligands, PDC-TREM associates with PlexinA1. After sub 
optimal CpG treatment, treatment with the PlexinA1 ligand, sema6D treatment induces 
IFNα production [84]. The concurrent stimulation with sem6D and suboptimal CpG 
induces PI3K, ERK1/2, and  IKKα/β phosphylation [84]. These signaling molecules are 
involved in IFNα production (Scheme 6). PDC-TREM is required for CpG induced IFNα 



























Diagram 11 TLR and PDC-TREM signaling 
! 81!
produce significantly less IFNα, but continue to produce equal levels of IL-12, IL-6, and 
TNFα [84].   
 
Mammalian target of rapamycin  
The mammalian target of rapamycin (mTOR) signaling promotes pDC production 
of type I IFN [82, 98].  The mTOR signaling cascade is activated by 
phosphatidylinositide 3-kinase (PI3K). When PI3K is activated by phosphorylation, it 
activates mTOR, which results in the phosphorylation and nuclear localization of IRF7, a 
critical step in pDC type I IFN production. Both TLR and PDC-TREM signaling 
phosphorylate PI3K, thus both may promote mTOR activation [84, 99, 100].  
Additionally, PI3K is a known target of ERα [99, 101, 102]. In epithelial and 
endothelial cells, ERα binds to the p85alpha regulatory subunit of PI3K and induces 
activation of PI3K and mTOR. Furthermore, the mTOR pathway is overactive in SLE. In 
mice with lupus nephritis, glomerular PI3K and mTOR activity were increased compared 












pDC expression of PDC-TREM is required for IFNα production, a key cytokine 
in lupus pathogenesis. Pre-disease ERαKO NZM mice have reduced frequencies of PDC-
TREM+ pDCs compared to pre-disease WT NZM mice, suggesting ERα signaling 
impacts PDC-TREM expression. Additionally NZM mice have higher frequencies of 
PDC-TREM+ pDCs compared to B6 control mice, thus expression of PDC-TREM is 
associated with disease. Furthermore, ERαKO does not impact PDC-TREM levels in B6 
mice, suggesting ERα’s impact on PDC-TREM expression occurs in response to disease 
specific stimuli. One such stimuli is lupus immune complexes which, stimulate TLR7/9 
in pDCs. I hypothesized ERα signaling promotes TLR mediated PDC-TREM 
surface expression and this promotion occurs through an estradiol mediated 
increase in pdc-trem RNA expression.  
 
pDC Activated pDC 
ERα 
TLR ligand 
Diagram 12  
Aim III Hypothesis 




ERα signaling impacts TLR mediated induction of PDC-TREM surface expression on 
BM derived pDCs from NZM mice 
 
To determine if the absence of functional ERα signaling impairs PDC-TREM 
expression in response to TLR stimulation, we treated BMDCs from Flt3L driven 
cultures, containing a mixture of pDCs and cDCs, from WT and ERαKO NZM mice with 
the TLR 9 ligand, CpG DNA, and measured pDC activation.  We first confirmed that 
PDC-TREM surface expression is increased 12 and 18 hours after TLR9 stimulation 
(Figure 26).! 





after 18 hours 
of TLR9 stimulation for the remainder of experiments. As shown in Figure 27A, ERα 
deficiency reduced the frequency of pDCs expressing PDC-TREM. In the same cultures, 
ERα deficiency also reduced the frequency of MHCII expression on both pDCs and cDCs 
following TLR 9 stimulation (Figure 28). There was no induction of PDC-TREM in 
unstimulated controls (Figure 27B). To determine if this finding correlated with a 
reduction in inflammatory cytokine production we measured levels of Il-6, TNF-α, and 
Il-12p40 in the supernatant. We did not see a change in levels of any of these cytokines 
between genotypes after 18 hours of TLR 9 stimulation. (Figure 29) This finding  













Figure 26 Figure 26. PDC-TREM 
surface expression on 
BM derived pDCs after 
T L R 9 s t i m u l a t i o n . 
BMDCs from WT NZM 
mice were treated with 
TLR9 agonist (CpG 1ug/
mL) for 6, 12, and 18 
h o u r s . P D C - T R E M 
e x p r e s s i o n  w a s 
m e a s u r e d b y f l o w 
cytometry. 
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suggestd the change in activation status does not correlate with a change cytokine 
production. Alternatively, our culture system consists of a mixture of pDCs, mDCs, and 
LDCs, which may dilute any change in cytokine production cause by one cell type. To 
address this issue, we sorted a pure population of Flt3L derived pDCs from B6 WT and 
ERαKO to measure TLR induced cytokine production. At 5 and 18 hours we did not 
detect a difference in Il-6, TNF-α, and Il-12p40 production between the genotypes 
(Figure 32). This finding suggests ERα signaling does not impact TLR mediated 
production of these cytokines. 
Since PDC-TREM surface expression can also be induced by TLR 7 stimulation 
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Figure 27. TLR  ligand induced PDC-TREM expression on BM derived DCs from NZM2410 mice.  BM 
from WT (n=6) and ERαKO (n=6) 10-14 week old female NZM2410 mice was cultured with 10% Flt3L for 7 
days under low estrogen conditions. One day 7 cells were harvested and the entire mixture of pDCs and 
cDCs were plated at a concentration of 2 million/mL and stimulated with 1ug of CpG (TLR9 ligand) for 18 
hours. Frequency of PDC-TREM+ pDCs (CD11c+B220+) and MFI of PDC-TREM on pDCs (A).  Frequency 
of PDC-TREM+ pDCs and MFI of PDC-TREM on pDCs treated with PBS control (B).  Representative flow 
cytometry, shaded histograms represent PBS control (C). Frequency of PDC-TREM+ pDCs  from WT and 
ERαKO NZM mice after TLR9, TLR 7 (loroxibine 200ug/mL), and IFNα 100IU stimulation (D). Results are 
expressed as the median ±IQR. Statistical analysis performed with Mann Whitney analysis. Data obtained 
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 with TLR 7 ligand (Loroxibine) and IFNα and measured PDC-TREM surface 
expression. We found a trend towards a reduced frequency of PDC-TREM+ pDCs after 















ERaKO  - - - 
Figure 28. TLR  ligand induced 
MHCI I express ion on BM 
derived DCs from NZM2410 
mice.  BM from WT (n=6) and 
ERαKO (n=6) 10-14 week old 
female NZM2410 mice was 
cultured with 10% Flt3L for 7 days 
under low estrogen conditions. 
One day 7 cells were harvested 
and the entire mixture of pDCs 
and cDCs were plated at a 
concentration of 2 million/mL and 
stimulated with 1ug of CpG (TLR9 
ligand) for 18 hours. Frequency of 
MHCII+ pDCs (CD11c+B220+) and 
MFI of MHCII on pDCs (A).  
Frequency of MHCII+ pDCs and 
MFI of MHCII on pDCs treated 
with PBS control (B). Frequency of 
MHCII+ cDCs (CD11c+B220-) and 
MFI of MHCII on cDCs (C).  
Frequency of MHCII+ cDCs and 
MFI of MHCII on cDCs treated 
w i t h  P B S  c o n t r o l  ( D ) . 
Representative flow cytometry, 
shaded histograms represent PBS 
c o n t r o l ( E , F ) R e s u l t s a r e 
expressed as the median ±IQR. 
Statistical analysis performed with 
Mann Whitney analysis. Data 
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Figure 29. TLR  ligand induced cytokine production by BM derived DCs from NZM2410 mice.  BM 
from WT (n=8) and ERαKO (n=6) 10-14 week old female NZM2410 mice was cultured with 10% Flt3L for 
7 days under low estrogen conditions. One day 7 cells were harvested and the entire mixture of pDCs and 
cDCs were plated at a concentration of 2 million/mL and stimulated with 1ug of CpG (TLR9 ligand) for 18 
hours. Production of IL-6, TNF-alpha, and IL12p40 were measued by ELISA. Results are expressed as 
the median ±IQR. Statistical analysis performed with Mann Whitney analysis. Data obtained in 3 separate 
experiments. 
 
ns ns ns 
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suggests ERα impacts both TLR7 and 9 mediated PDC-TREM expression. However, 
ERα does not greatly impact IFNα mediated PDC-TREM expression.  
 
ERα signaling impacts PDC-TREM expression on BM derived pDCs from B6 mice.  
 To determine if ERα’s effect on PDC-TREM expression was strain/disease 
specific we sorted pDCs (live, CD11c+B220+CD11b-) from Flt3L driven BMDCs from 
WT and ERαKO B6 mice that were age and sex matched with the NZM mice and 
stimulated the pDCs with the TLR9 ligand, CpG DNA.!
 In this pure pDC population, ERα deficiency also reduced PDC-TREM and MHCII 










ERaKO  - - - 
Figure 30. TLR 9 ligand induced PDC-TREM expression on BM derived pDCs from B6 mice.  
BM from WT (n=5) and ERαKO (n=6) 10-14 week old female C57/BL6 mice was cultured with 10% 
Flt3L for 7 days under low estrogen conditions. One day 7 cells were harvested and pDCs (CD11c+, 
B220+, CD11b-) were sorted using flow cytometry and plated at a concentration of 2 million/mL and 
stimulated with 1ug of CpG (TLR9 ligand) or PBS control for 18 hours. Frequency of PDC-TREM+ 
pDCs and MFI of PDC-TREM on pDCs (A). Frequency of PDC-TREM+ pDCs and MFI of PDC-TREM 
on pDCs treated with PBS control (B). Results are expressed as the median ±IQR. Statistical 
analysis performed with Mann Whitney analysis. Flow cytometry plots are representative of data in 
dot plots and shaded histograms represent PBS treated controls for each genotype (C).  Data 
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intrinsic not dependent on changes in the pDCs caused by the disease state. (Figure 30 
and 31). Therefore the reduction in PDC-TREM expression may represent a conserved 
mechanism by which ERα impacts pDC activation and may be applicable to the 
regulation of pDC in other models.!
  
MTOR pathway activation is increased in ERαKO pDCs after TLR stimulation 
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ERaKO  - - - 
Figure 31. TLR 9 ligand induced MHCII expression on BM derived pDCs from B6 
mice.  BM from WT (n=5) and ERαKO (n=6) 10-14 week old female C57/BL6 mice was 
cultured with 10% Flt3L for 7 days under low estrogen conditions. One day 7 cells were 
harvested and pDCs (CD11c+, B220+, CD11b-) were sorted using flow cytometry and plated 
at a concentration of 2 million/mL and stimulated with 1ug of CpG (TLR9 ligand) or PBS 
control for 18 hours. Frequency of MHCII+ pDCs and MFI of MCHII on pDCs (A). 
Frequency of MHCII+ pDCs and MFI of MHCII on pDCs treated with PBS control (B). 
Results are expressed as the median ±IQR. Statistical analysis performed with Mann 
Whitney analysis. Flow cytometry plots are representative of data in dot plots and shaded 




















Since ERα signaling positively impacts PDC-TREM expression on pDCs, and 






















ERaKO  - - - 
Figure 33. TLR 9 ligand 
induced PS6 expression on 
BM derived pDCs from 
NZM mice.  BM from WT 
(n=4) and ERαKO (n=4) 
10-14 week old female 
NZM2410 mice was cultured 
with 10% Flt3L for 7 days 
u n d e r  l o w e s t r o g e n 
conditions. One day 7 cells 
were harvested and plated at 
a concentration of 2 million/
mL and stimulated with 1ug 
of CpG (TLR9 ligand) or PBS 
c o n t r o l f o r 1 8 h o u r s . 
Frequency of PS6+ pDCs (A), 
PS6+ mDCs (B), and PS6+ 
LDCs (C) . Resu l ts are 
expressed as the median 
±IQR. Statistical analysis 
p e r f o r m e d w i t h M a n n 
Whi tney analys is. F low 
c y t o m e t r y p l o t s  a r e 
representative of data in dot 
plots and shaded histograms 
represen t PBS t rea ted 
controls for each genotype.  
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Figure 32. TLR  ligand induced cytokine 
production by BM derived pDCs from B6 
mice.  BM from WT (n≥6) and ERαKO (n≥6) 
10-14 week old female B6 mice was cultured 
with 10% Flt3L for 7 days under low estrogen 
conditions. One day 7 cells were harvested and 
pDCs (CD11c+, B220+) were sorted using flow 
cytometry and plated at a concentration of 105 
cells/mL and stimulated with 1ug/mL of CpG 
(TLR9 ligand) for 5 hours. For 18 hour 
stimulation the pDCs were plated at a 
concentration of 2 million/mL and stimulated 
with 1ug of CpG (TLR9 ligand). IL-6 and TNF-
alpha were measured at 5 hours and TNF-alpha 
and  IL12p40 were measured at 18 hours. (B). 
Results are expressed as the median ±IQR. 
Statistical analysis performed with Mann 

















































 we hypothesized ERα signaling would also positively impact TLR mediated 
mTOR pathway activity. To test this hypothesis we measured mTOR activity via levels 
of phosphorylated S6 kinase in WT and ERαKO pDCs 18 hours after TLR 9 stimulation. 
We found that ERαKO pDCs expressed more phosphorylated S6, indicating that the 
mTOR pathway is more active in ERαKO pDCs and mDCs compared to WT after TLR 
stimulation. We hypothesized this finding may  be due to a delayed onset of mTOR 
pathway activation in ERαKO. We measured mTOR activation in WT and ERαKO pDCs 
at short time points, 15 and 30 mins post TLR stimulation.  At these time points, pDCs do 
not express phosphorylated S6. However, mDCs do expression phosphorylated 6S, 
indicating this pathway is more active in the mDCs compared to pDCs. Additionally, 
mDCs at 18 hours express more PS6 compared to pDCs, also suggesting this pathway is 
more important in ERα signaling in mDCs compared to pDCs.  
 
Estradiol treatment does not impact TLR mediated PDC-TREM expression  
Since ERαKO pDCs expressed lower levels of PDC-TREM after TLR activation, 
we hypothesized estradiol treatment may increase TLR mediated PDC-TREM expression 
on pDCs. To test this hypothesis, we treated BM derived ERα+/+ pDCs with 0, 1, 2, 5, and 
10nM of estradiol at the time of TLR 9 stimulation (1ug/mL). We did not detect a change 
in pDC-TREM expression with any concentration of estradiol treatment (Figure 34A). 
This finding indicates that at an optimal level of TLR9 stimulation (1ug/mL) increasing 
estradiol levels do not impact PDC-TREM surface expression. Additionally, the addition 
of estradiol alone, without TLR stimulation, does not induce the surface expression of 
! 90!
 
PDC-TREM. The literature shows that estradiol can induce optimal DC activation in the 
presence of suboptimal levels of TLR ligand. Therefore, we hypothesized estradiol may 
induce an effect on PDC-TREM when TLR ligand levels are suboptimal. To test this 
hypothesis we added 10nM of estradiol and 0.1 or 0.25ug/mL of TLR9 ligand to BM 
derived pDCs cultures. Under these conditions we did not detect any change in the 
frequency of pDCs expressing PDC-TREM with the addition of estradiol (Figure 34B). 
However, we detected a slight reduction in the frequency of PDC-TREM+ pDCs with the 
addition of estradiol to BMDC cultures from ERαKO B6 mice (Figure 34B). This 
finding, although preliminary, suggests the ERαKO protein may act as a negative 
regulator of TLR ligand induced PDC-TREM expression. This hypothesis is in support of 
the finding that the ERαKO mice are protected from disease, however, the full ERα 
deficient mice are not (Cunningham, manuscript in preparation).  This observation 
suggests the truncated ERαKO protein may be protective in disease. Therefore a future 
study examining this dominant negative mechanism may be useful. Additionally, the 
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Figure 34. The effect of estradiol treatment on TLR 9 ligand 
stimulated BM derived pDCs. BM from WT and ERαKO mice was 
cultured with 10% Flt3L for 7 days under low estrogen conditions. On 
day 7, cells were harvested and plated at a concentration of 2 million/mL 
and stimulated with estradiol and/or CpG (TLR9 ligand) or PBS control 
for 18 hours. Frequency of PDC-TREM+ BM derived pDCs obtained 
from WT NZM (n=3) mice after treatment with  1ug/mL of CpG and 
increasing amount of estradiol (1-10nM) (A) Frequency of PDC-TREM+ 
BM derived pDCs obtained from WT (n=5) and ERαKO (n=4) B6 mice 
after treatment with  10nM of estradiol and low amounts of CpG (0.1 or 
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pDCs may play a role in PDC-TREM expression.  The pre programming effect of 
estradiol/ERα on pDCs IFNα production has been shown in previous studies[16].! 
Exposure of BM derived pDCs to IFNα during Flt3L culture enhances the reduction of 
PDC-TREM expression on ERαKO pDC.   
We sorted pDCs from Flt3L ligand driven BM cultures from B6 mice and 
detected a reduction in TLR mediated PDC-TREM expression on ERαKO pDCs. We also 
stimulated whole Flt3L driven BM cultures from WT and ERαKO NZM mice with TLR9 
ligand and detected a significant and repeatable reduction in the frequency of PDC-
TREM+ pDCs in cultures from ERαKO NZM mice. We then stimulated whole Flt3L 
driven BM cultures from WT and ERαKO B6 mice with TLR9 ligand and did not detect 
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Figure 35. TLR  ligand 
i n d u c e d  P D C - T R E M 
expression on BM derived 
DCs pre-treated with IFNα. 
BM f rom WT (n≥4) and 
ERαKO (n≥4) female B6 mice 
was cultured with 10% Flt3L 
for 7 days under low estrogen 
conditions with or without 
100IU of recombinant mouse 
IFNα. On day 7 cells were 
harvested and the entire 
mixture of pDCs and cDCs 
were plated at a concentration 
of 2 million/mL and stimulated 
with 1ug of CpG (TLR9 ligand) 
(A), 200ug/mL of loroxibine 
(TLR7 ligand) (B), or 100IU of 
IFNα (C) for 18 hours. The 
DCs were alsot reated with 
1ug/mL of CpG and 100IU of 
IFNα simultaneously (E). 
Frequency of PDC-TREM+ 
pDCs (CD11c+B220+) was 
measured with flow cytometry. 
Representative flow cytometry, 
histogram of TLR9 stimulated 
BMDCs (D).  Results are 
expressed as the median ±SD. 
Statistical analysis performed 
with Mann Whitney analysis. 
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 A major difference between the NZM and B6 Flt3L cultures is the presence of an 
inflammatory state in the NZM mice, both in vitro in the culture dish and prior to culture 
in the mouse. Whether the inflammatory state is actively present in the culture dish or the 
precursor cells have been exposed to an inflammatory environment in vivo, in this state of 
inflammation pDCs may become more sensitive to TLR stimulation. Increased sensitivity 
to TLR 9 ligand may explain the difference in PDC-TREM expression between NZM and 
B6 mice. Furthermore, we saw a reduction in TLR mediated PDC-TREM expression on 
sorted pDCs from B6 mice. Since the sorted pDCs make up the entirety of the culture, the 
cells will have a greater availability of TLR 9 ligand compared to mixed cultures. Thus, 
explaining the difference between sorted and mixed pDCs cultures in TLR mediated 
expression of PDC-TREM. Based on this evidence we hypothesized an inflammatory 
state enhances the reduction in TLR mediated PDC-TREM expression on ERαKO pDCs. 
To test this hypothesis we treated Flt3L driven BM cultures with 100U/mL of IFNα on 
day 0 of culture and measured TLR and IFNα mediated PDC-TREM expression on pDCs 
at day 7. We found that TLR 9 ligand, TLR 7 ligand, and IFNα treatment of BM derived 
DCs treated with IFNα showed trends towards reduced PDC-TREM expression on pDCs 
from ERαKO mice compared the pDCs from ERαKO mice that were not treated with 
IFNα during culture (Figure 35). This finding suggests that the reduction in ERαKO pDC 
PDC-TREM expression is mediated by both TLR ligands and IFNα and that both of these 
signals are required for ERα’s impact on PDC-TREM expression.  To determine if the 
effect was because of pre-programming provided by the inflammatory environment or 
was an immediate effect of IFNα signaling we treated BM derived DC cultures with both 
TLR 9 ligand and IFNα for 18 hours. Under these conditions, there was no change in 
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PDC-TREM expression between WT and ERαKO pDCs, indicating that IFNα’s impacts 
PDC-TREM expression by ’programming’ the pDCs for sensitivity to future TLR 
stimulation. Since the change in PDC-TREM expression in the IFNα pre-treated cultures 
was the results of reduced expression of PDC-TREM on ERαKO pDCs rather than an 
increase of PDC-TREM on WT pDCs, these findings also suggest the ERαKO protein 
may act as a negative regulator of pDC activation. Given the findings in with estradiol 
treatment and disease protection provided by the ERαKO, this dominant negative effect 
should be studied in greater detail in the future.  
ERα signaling positively regulates pdc-trem mRNA levels prior to TLR stimulation 
To investigate the mechanism by which the functional mutation of ERα reduced 
TLR mediated PDC-TREM we hypothesized ERα could impact three aspects of pDC 
development that contribute to pDC functionality. The literature demonstrates 
estradiol/ERα impacts pDC type I IFN production by ‘pre-programming’ the pDCs in 
vivo to be more responsive to ex vivo TLR stimulation. Although some literature supports 
a stimulatory role of estradiol at the time of TLR stimulation, our data suggests ERα 
impacts PDC-TREM expression by pre-programming pDC function during development. 
We investigated the impact of ERα on pDC expression of the pDC master regulator gene 
E2-2, TLRs7 and 9, and PDC-TREM. 
 E2-2 is the master transcriptional regulator of pDC development. Without E2-2 
pDCs cannot develop to maturity or produce type I IFN [71]. Furthermore, if E2-2 
expression is lost in mature pDCs the cells will revert back to a conventional DC 
phenotype [72].   We hypothesized ERα may impact the expression of E2-2 and thereby t!
! 94!
 he overall phenotype of the pDCs. To test this hypothesis we measured levels of E2-2 
transcripts in Flt3L derived pDCs from WT and ERαKO B6 mice. E2-2 transcript levels 
were equal in WT and ERαKO pDCs (Figure 36 A). This finding suggests ERαKO pDCs 
develop into fully mature pDCs. This finding also establishes that ERαKO, although 
important in pDC development, does not impact the overall pDC phenotype of cells 
produced by the Flt3L culture.  
 We hypothesized ERαKO pDCs are less responsive to TLR ligands because they 
express reduced levels of TLR 7/9 and IFNα receptor (IFNAR). To test this hypothesis 
we measured the levels of the transcripts for these receptors in BM derived pDCs from 
WT and ERαKO B6 mice. There was no difference in transcript levels of TLR7, TLR9, 










































Figure 36. Expression of pDC genes in TLR naïve pDC. BM from 
WT (n=5) and ERαKO (n=6) female 10-14 week old B6 mice was 
cultured with 10% Flt3L for 7 days under low estrogen conditions. On 
day 7 cells were harvested and pDCs (CD11c+B220+) cells were sorted 
via flow cytometry. The cells were immediately processed for RNA 
extraction and transcript levels were measured by qPCR The 
transcripts measured were E2-2 (A), TLR9, TLR7, IFNAR (B), PDC-
TREM, and DAP12 (C). Results are expressed as the median ±IQR. 
Statistical analysis performed with Mann Whitney analysis. Data 









































antibodies for TLR7 and 9 are not available this finding provides the best evidence that 
















Figure 37. Expression of pDC genes after TLR stimulation. BM from 
WT (n=6) and ERαKO (n=6) female 10-14 week old B6 mice was 
cultured with 10% Flt3L for 7 days under low estrogen conditions. On 
day 7 cells were harvested and pDCs (CD11c+B220+) cells were 
sorted via flow cytometry. The sortd cells were plated at a concentration 
of 5x105/mL and stimulated with TLR9 ligand (CpG 1ug/mL) for 5 
hours. The cells were immediately processed for RNA extraction and 
transcript levels were measured by qPCR The transcripts measured 
were PDC-TREM, DAP-12 (A), IFNα and IFNβ (B), and IRF 7 (C). 
Results are expressed as the media ±IQR. Statistical analysis 





















































Since PDC-TREM expression was reduced in ERαKO pDCs compared to WT 
pDCs after TLR stimulation we hypothesized the ERαKO pDCs have less transcripts of 
PDC-TREM and PDC-TREM associated molecules. To test this hypothesis we measured 
the transcripts of PDC-TREM and its associated signaling molecule DAP12 in BM 
derived pDCs from WT and ERαKO B6 mice prior to stimulation with TLR ligands. The 
ERαKO pDCs expressed lower levels of PDC-TREM mRNA compared to WT pDCs 
(Figure 36C). Additionally, there was a trend of reduced DAP12 transcripts in the 
ERαKO pDCs compared to PDC-TREM (Figure 36C). The reason for DAP12 and PDC-
TREM levels being reduced at different rates could be that DAP-12 acts a signaling 
molecule for other pDCs surface receptors. Although PDC-TREM surface expression is 
only detected after TLR stimulation, PDC-TREM mRNA is detected in unstimulated 
pDCs [84]. Prior to TLR stimulation ERα signaling positively impacts PDC-TREM 
mRNA levels and may increase the expression of  he adaptor molecule DAP12. The 
regulation of PDC-TREM mRNA may represent the mechanism by which ERα signaling 
pre-programs pDCs to express increased levels of surface PDC-TREM after TLR 
stimulation.  
ERα signaling does not regulate pdc-trem mRNA levels after TLR stimulation 
To determine if ERα signaling also reduced PDC-TREM mRNA levels after TLR 
stimulation we measured the expression of PDC-TREM and DAP-12 in pDCs from B6 
WT and ERαKO mice 5 hours after TLR stimulation.  After TLR stimulation ERαKO 
pDCs did not express significantly lower levels of PDC-TREM or DAP-12 transcripts 
(Figure 37A) This finding suggests that ERα signaling does not likely impact PDC-
TREM and DAP-12 expression after TLR stimulation. We also measured express of 
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IFNα and IFNβ transcript levels are the 5 hours time point post TLR stimulation. There 
was no change in IFNα and IFNβ transcript levels between genotypes (Figure 37B). 
Although, this finding suggest ERα signaling does not impact IFN production, the lack of  
difference is likely due to the time point selected. These finding suggest ERα signaling 
does not regulate PDC-TREM expression after TLR sitmulation, but rather through an 
effect of naïve pDC expression of PDC-TREM transcripts prior to TLR stimulation. 
 
Estrogen response elements in PDCTREM promoter 
 
 To determine if the PDC-TREM promoter contains estrogen receptors binding 
sites, estrogen response elements (EREs), we used matinspector software to identify 
EREs in the promoter of PDC-TREM. We searched for EREs located within 5,000 BPs 
upstream of the PDC-TREM exon 1. The software identified 6 EREs within the PDC-
TREM promoter. Two of these EREs were specific for ERβ. The remaining 4 were 
specific for ERα. The ERα EREs were located at position 1082, 2867, 4065, and 4706 
(with 5000 being exon1) (Figure 38A). The ERE located at the position 1082 contained 
the ERE core sequence GACC (Figure 38B and C). The three remaining EREs contained 
the GTCA core sequence (Figure 38D and E). The EREs all contained core sequences as 
well as >85% similarity with the surrounding 19bp around the core sequences (Table 1). 













Figure 38. Potential estrogen response elements located in the PDC-TREM promoter. We identified 6 estrogen response 
elements (EREs) in the 5,000bp upsteam of PDC-TREM exon 1 (A). Matinspector software was used to obtain potential 
binding regions with 100% core sequence similairty and .85% matrix similarity. The matrix for ERα.03 is depicted in (B and C) 
and the matrix for ERα.04 is depicted in (D and E). In C and E nucleotides in capital letters denote core sequence and 














position End position Strand Core sim. Matrix sim. Sequence 
ERE ERα.03 1064 1082 + 1 0.826 aagaggcaatgaGACCtag 
ERE ERα.04 2867 2885 + 1 0.912 ggggGTCAggctgggctca 
ERE ERβ.01 3021 3039 - 1 0.923 acagGTCAaatggccttgt 
ERE ERβ.01 3688 3706 - 1 0.91 gcagGTCAccctgggagga 
ERE ERα.04 4065 4083 + 1 0.902 attgGTCAgtctgccggca 
ERE ERα.04 4706 4724 - 1 0.874 cctgGTCAgggtgggggat 
Table 1. Estrogen Response Elements in PDC-TREM Promoter  
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Summary 
- ERα signaling positively impacts TLR mediated PDC-TREM surface expression 
on BM derived pDCs from NZM and B6 mice 
- Estradiol treatment at time of TLR stimulation does not impact PDC-TREM 
surface expression in WT BM derived pDCs.  
- WT and ERαKO BM derived naïve pDCs from B6 mice express equal levels of 
E2-2, TLR7, TLR9, and IFNAR transcripts. 
- ERαKO BM derived naïve pDCs from B6 mice have significantly less PDC-
TREM transcripts and a trend towards reduced DAP-12 transcript levels 
compared to WT BM derived naïve pDCs 
- Estradiol treatment and pre-treatment with IFNα reduced TLR mediated PDC-










4.4  Discussion 
PDC-TREM protein is expressed on the surface of pDCs after TLR stimulation 
and is not expressed on TLR ligand naïve pDCs [84]. However, in naïve pDCs PDC-
TREM transcripts are detectable [84]. We found that ERα signaling positively impacts 
surface expression of PDC-TREM after TLR stimulation. Additionally, ERα signaling 
positively impacts PDC-TREM transcript levels in TLR ligand naïve pDCs. These 
findings suggest ERα signaling impacts TLR mediated PDC-TREM expression by 
mediating naïve pDC’s potential to respond to TLR ligands. ERα’s impact on PDC-
TREM transcripts prior to TLR stimulation likely accounts for the majority of regulation 
because estradiol treatment at the time of TLR stimulation does not alter PDC-TREM 
surface expression. Therefore, ERα signaling likely  ‘pre-programs’ a pDC’s ability to 
respond to TLR ligand. The pre-programming by estradiol/ERα has been previously 
reported. Seillet et al found in vivo estradiol signaling through ERα increased in vitro 
TLR mediated pDC IFNα production [16]. Our results suggest that PDC-TREM 
expression is likely also regulated by estradiol mediated pre-programming.  Additionally, 
our finding provides a possible mechanism by which ERα signaling impacts IFN 
production.  
 Inflammation likely impacts ERα’s role in PDC-TREM expression. We reported 
enhanced differences in pDC activation between WT and ERαKO  pDCs from NZM 
mice compared to B6 mice both in vivo and in vitro.  In vivo, it is tempting to attribute 
this enhancement to the presence of additional immune stimuli in NZM mice. However, 
when pDCs are provided equal doses of TLR ligand in vitro, pDCs from WT and ERαKO 
NZM mice maintain the greater differences in pDC activation compared to B6 mice. This 
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finding suggests a mechanism beyond increased stimuli levels is responsible for the 
difference. We hypothesized the increased inflammation in NZM mice contributes to 
ERα’s impact on TLR mediated pDC activation. To test the hypothesis we used IFNα to 
simulate an inflammatory environment in the culture during Flt3L mediated DC 
development. We found that the addition of IFNα during culture broadened differences in 
PDC-TREM expression between TLR stimulated WT and ERαKO pDC from B6 mice. 
Although this finding was not significant for each individual stimuli, the trend was seen 
in each stimuli. This finding suggests that inflammation enhances ERα’s role in TLR 
mediated pDC activation. In the literature, evidence shows that ERα signaling impacts 
inflammatory responses [56]. Although controversy exists in this field, ERα likely 
enhances and represses inflammation depending on the scenario. Precisely how ERα 
takes on this dual role is under investigation.  
 Inflammation also regulates ERα signaling. In an in vivo mouse model of joint 
inflammation, affected joints had reduced levels of ERα protein compared to unaffected 
joints [107]. Molecularly, in a breast cancer cell line NFkB repressed ERα and β 
signaling activity and RelB via Blimp1 inhibited the synthesis of ERα [108]. 
Additionally, NFkB and ERα can act synergistically to regulate gene expression [108]. 
IFNα also impacts ERα signaling. Treatment of a breast cancer cell line with IFNα 
increased levels of ER protein [109]. IFNα treatment of mouse spleen cells increased 
levels of ERα transcripts and protein [110]. Since ERα singling enhances IFN production, 
this finding suggests there is a positive feedback loop between ERα and IFNα signaling 
[110].  
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 There is also evidence in DCs for inflammation altering ERα signaling. The 
requirement for the AF-1 domain of ERα changes depending on if the DCs were grown 
under inflammatory versus steady state conditions [56]. Also, our laboratory has 
preliminary data suggesting inflammatory DCs express higher levels of ERα transcripts 
compared to steady state DCs. Given this evidence, it is possible IFNα enhances the 
pDC’s ability to respond to inflammatory stimuli and our data suggests IFNα enhances 
the pDC’s ability to expression PDC-TREM after TLR stimulation.  
The ERαKO mouse is not a model of complete ERα deletion. Rather, it expresses 
low levels of a mutant ERα protein that lacks the AF1 domain, but maintains the DNA 
binding, ligand binding, and AF2 domain. This mutant protein resembles both the 
naturally expressed ERα 46 spice variant and the engineered AF1 mutant (Diagram 3). 
Our data suggests the mutant ERαKO protein may impact pDC activation. When DCs 
were pre-treated with IFNα, the difference in PDC-TREM expression increase between 
genotypes. The increase was a result of ERαKO pDCs expressing reduced levels of PDC-
TREM in response to IFNα pre-treatment. Additionally, estradiol treatment did not 
impact WT pDC expression of PDC-TREM, but it did reduce PDC-TREM expression on 
ERαKO pDCs. This evidence suggests ERαKO mutant protein may be reducing pDC 
activation status. Alternatively, the ERαKO pDCs could be less responsive to TLR 
stimulation because of the hormonal milieu in the mice. The ERαKO mice have 
significantly higher estrogen and testosterone levels compared to WT mice [1]. Increases 
in these hormones could provide an anti inflammatory effect. Therefore this possibility 
should be investigated. However, our laboratory has found that these changes in hormone 
levels are not responsible for disease protection in the ERαKO mice. When the hormone 
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levels were normalized in ERαKO NZM mice, the mice were protected from disease. 
Additionally, the mice were not protected in the absence of estrogen, suggesting ERαKO 
mutant protein requires estrogen for its function. Although the possibility that estrogen 
signals through another receptor to protect from disease exists, our laboratory found that 
the complete absence of ERα does not protect mice from disease. This evidence suggests 
the presence of estrogen mediated ERαKO mutant signaling is necessary for disease 
protection in NZM mice. Therefore, it is possible that the ERαKO protein is mediating 
the reduction in PDC-TREM level.  
 Although, the presence of the natural isoform ERα46 is controversial, there is 
evidence supporting its existence and function. ERα46 is expressed in human endothelial 
cells and is located in the plasma membrane, cytosol, and nucleus. The plasma membrane 
ERα46 mediates rapid changes in eNOS activity [111]. Furthermore, ERα46 can function 
as a dominant negative to inhibit the transcriptional activities of ERα66 (classical ERα) 
[112]. There is also evidence the 46KD isoform is expressed and has function in immune 
cells. In human macrophages, the primary variant of ERα is the estradiol sensitive 46KD 
isoform. Furthermore its levels increase with the monocyte to macrophage transition [57]. 
The expression of this splice variant is mediated by a different promoter than the ERα66. 
 In dendritic cells the engineered ERα AF1 mutant suggests the mutant ERαKO 
protein may play a role in cell function. Like the AF1 mutant, the ERαKO mutant lacks 
the AF1 domain. Using the mutant AF1 null ERα, the later stages of inflammatory 
dendritic cells development was not impacted by a lack of AF1 domain. However, the 
complete absence of ERα did impact later stages of DC development. This finding 
suggests the ERα protein lacking AF1 has a function in later stages of DC development. 
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Since the ERαKO protein resembles the AF1 null mutant, it may also impact late stage 
DC development. All together this evidence suggests the ERαKO mutant protein may 
play a role in disease protection. However, we need to strengthen our evidence for the 
















ERα signaling positively impacts TLR mediated surface expression of PDC-
TREM. ERα signaling likely mediates this effect by pre-programming pDCs to be more 
responsive to TLR stimulation through a developmental mechanism. (Scheme7). One 
mechanism that could mediate this effect is by ERα signaling increasing levels of PDC-
TREM transcripts in TLR naïve pDCs. The increase in PDC-TREM transcripts occurs 
without altered expression of TLR7, 9 or IFNAR. This finding suggests ERα signaling 
impacts signaling factors downstream of TLRs to alter TLR responsiveness in a 
developmental manner. It is possible the ERαKO mutant protein acts as a dominant 
negative to cause this effect. 
 











Diagram 13  
Aim III Summary 
ERα signaling increases TLR ligand naïve pDC expression of Pdc-trem and this may contribute to 
increased TLR mediated PDC-TREM surface expression    
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4.6 Future directions 
 Future work may focus on the regulation of PDC-TREM. Independent of ERα, 
little is know about the regulation of PDC-TREM. Since transcripts are expressed prior to 
TLR stimulation, it should be determined if TLR signaling promotes the translation or 
intracellular trafficking of PDC-TREM. Once this is understood, the effect of ERα on this 
process can be investigated. Since ERα signaling impacts PDC-TREM transcript levels, it 
is important to understand if ERα impacts the transcription of the gene or stability of the 
transcript. If ERα impacts transcription, we should determine if ERα directly regulates 
the promoter or is it acts indirectly through a different transcription factor, which then 
regulates gene expression.  
 Additionally, the possibility of mutant ERαKO protein acting as a dominant 
negative should be investigated. This may be done by studying PDC-TREM levels in 
ERα null mice and hormone controlled ERαKO mice. Additionally, work needs to be 
done to detect this mutant protein in pDCs.  
 Lastly, ERα signaling impacts a vast amount of cell functions. Therefore, this 
work should be put into the context of the broader investigation into ERα regulation of 
immune cell function. Currently, our laboratory is exploring how ERα singling impacts 
the transcriptome of dendritic cells. This work will likely yield important information 





















Chapter 5 Closing remarks 
 
 NZM2410 mice lacking functional ERα signaling are protected from disease. The 
mechanism of disease protection is unknown. In this work we have determined that ERα 
signaling altered the activation status of pDCs in NZM2410 mice prior to the 
development of clinical disease without altering pDC number or maturation status. 
Specifically, ERα signaling positively impacted PDC-TREM and MCHII expression in 
pre-disease mice. The frequency of PDC-TREM+ pDCs is also increased in pre-clinical 
disease NZM2410 mice compared to controls, suggesting that PDC-TREM expression 
impacts disease pathogenesis. Simultaneously, ERα signaling positively regulated type I 


















Diagram 14  
Conclusions 
ERα signaling increased endogenous pDC activation state and IFN activity in 
pre-disease lupus prone mice 
 
ERα signaling programs naive pDCs for increased TLR responsiveness 
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for optimal type I IFN production by pDCs, ERα may regulate type I IFN activity via 
PDC-TREM.  Additionally, ERα’s impact on PDC-TREM expression and type I IFN 
signaling may explain disease protection in NZM2410 mice lacking functional ERα 
signaling.   
 Since ERα may impact disease by altering pDC expression of PDC-TREM, we 
explored the mechanism by which this regulation of pDC activation occurs. We found 
that ERα impacts TLR mediated induction of surface PDC-TREM expression in both B6 
and NZM2410 mice, indicating this mechanism occurs in both in the disease and non-
disease state. Furthermore, ERα signaling impacts PDC-TREM transcript levels prior to 
TLR stimulation indicating ERα signaling ‘pre-programs’ pDCs to express more surface 
PDC-TREM in response to TLR stimulation. Since PDC-TREM is required to type I IFN 
production, this finding may represent a mechanism by which ERα alters pDC IFN α 
production in response to TLR stimulation.  
 It is important to put this work into the context ERα’s role in SLE pathogenesis 
and the female predominance of SLE. Regarding ERα signaling in disease pathogenesis, 
ERα is a ubiquitously expressed transcription factor, which affects numerous cellular 
processes. Thus, it is likely that ERα impacts disease through multiple mechanisms 
including, but not limited to its impact on pDC activation. Additionally, ERα has been 
shown to alter both pro and anti-inflammatory processes, suggesting ERα may impact 
disease differently depending on the timing and cellular environment. Since ERα exerts 
numerous effects on physiologic processes it is difficult to completely understand its 
function and role in disease. Thus, our work is important because it addresses a single 
and specific aspect of ERα function. To further address ERα function in disease, we will 
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need to use cell specific and conditional ERα knockouts and ERα mutant models. 
Additionally, we need to place ERα’s impact on PDC-TREM transcript levels within the 
context of ERα’s impact on the entire transcriptome to fully understand ERα’s role in DC 
‘pre-programming’. Future work will address these issues. Regarding the female 
predominance of disease, the mechanism studied in this work along with other work in 
our laboratory can be translated into human studies. The human studies will allow us to 




























Chapter 6 Materials and Methods 
Mice: ERα deficient (ERαKO) mice on the C57BL/6 background (kind gift of Dr. Ken 
Korach, NIEHS, RTP, NC) were backcrossed for 12 generations to NZM2410 mice 
(Jackson Laboratory, Bar Harbor, ME) and congenic status was verified as previously 
described [55]. Female mice between 10 and 14 or 22-26 weeks of age were used for 
these experiments. All mice were maintained at the Ralph H. Johnson VAMC Animal 
Care Facility (Charleston, SC) using Institutional Animal Care and Use Committee 
approved protocols #421 and #498 originally approved August 2008 and 2011 
respectively. 
 
Spleen DCs: Spleens were harvested from mice and placed on ice in RPMI-media. The 
spleens were processed through 70um strainers and depleted of red blood cells with red 
blood cell lysis buffer (144 mM NH4Cl and 17 mM Tris, pH 7.6). After washing in 
estrogen-free RPMI-media (charcoal dextrane treated FBS in phenol red-free RPMI, 
pennicillin/streptomycin, ampicillin, and L-glutamine), the cells were counted and either 
placed in TRIzol (Life Technologies, Grand Island, NY) for RNA extraction or stained 
for flow cytometry. For flow cytometry, 4 million cells were washed 2x in PBS and 
resuspended in LIVE/DEAD Fixable Dead Cell Stain (Life Technologies) at a 
concentration 50ul/million cells. Cells were washed 2x in staining buffer (0.5% BSA, 
0.02% sodium azide in PBS) and treated with anti-CD16/CD32 for 5 minutes. Cells were 
then stained for surface antigens with the indicated conjugated antibodies in 50ul of 
staining buffer per million cells for 25minutes. All staining was performed in the dark on 
ice. The cells were washed 2x in staining buffer and re-suspended in 0.3 mLs of staining 
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buffer and acquired on the LSRFortessa cell analyzer (BD Biosciences, San Jose, CA). 
Analysis was preformed using FlowJo software (Treestar Ind, Ashland, OR). All cells 
analyzed were first identified as both singlets and live to eliminate debris and dead cells, 
respectively. pDCs were identified as CD11b-, B220+, SiglecH+. Serial gating was used to 
identify pDCs by identifying SiglecH+ cells in a pre-selected B220+, CD11b- population 
(Supplemental figure 2).  cDCs were identified as B220-, SiglecH-, CD11c+. Activation 
markers were measured on these populations of DCs as indicated. Fluorescence minus 
one controls were used as indicated to select gates.  
 
Bone marrow DCs: Bone marrow was flushed from the femurs and tibias of mice and 
processed through a 70um strainer and depleted of RBCs in the same manner as the 
spleen. The cells were either stained for flow cytometry or cultured to obtain bone 
marrow derived DCs (BMDCs). Total bone marrow was stained for flow cytometry and 
analyzed in the same manner as the spleen cells.   
For BMDC generation total BM was plated at a concentration of 1.5 x106 cells per 
mL in estrogen-free RPMI-media with 10% supernatant from a Flt3L producing cell line 
(a kind gift of Dr. Stephania Gallucci, Temple University). The BMDCS were harvested 
on day 7, counted, and re-plated at a concentration of 2 x106 cells per mL in estrogen-free 
RPMI for TLR ligand treatment. If indicated, pDCs were sorted from the total BMDC 
population using fluorescent activated cell sorting (FACS) and plated at a concentration 
of 2 x106 cells per mL in estrogen-free RPMI.  Cells were sorted under sterile conditions 
using the same staining protocol as the spleen cells. Samples were sorted on the BD 
MoFlo Astios High Speed Cell Sorter. pDCs were identified as singlets, live, CD11b-, 
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CD11c+, B220+.  The pDCs or total BMDCs were treated with either PBS or CpG DNA 
(TLR9 agonist) at 1ug/mL. After 18 hours, the cells were scraped from the plates and 
washed in PBS to prepare for staining for flow cytometry. One million cells were stained 
in the same manner as the spleen cells. BMDC populations were identified as followed; 
pDCs: CD11c+. B220+, mDC: CD11c+, B220-, CD11b+, and LDCs: CD11c+, B220-, 
CD11b-.  
 
Antibodies and reagents: Fluorescent conjugated antibodies including anti-mouse 
CD11c, CD11b, B220, SiglecH, mPDCA1, PDC-TREM, MHC II (I-A/I-E), and CD40 
were purchased from Biolegend (San Diego, CA). PE-conjugated anti-mouse Ly49Q was 
purchased from MBL International (Woburn, MA). LIVE/DEAD fixable near-IR dead 
cell staining kit was purchased from Life Technologies (Grand Island, NY). Mouse CpG 
DNA was purchased from Hycult Biotech (Canton, MA). All ELISAs were purchased 
from BioLegend (San Diego, CA) expect for the IFNα ELISA that was purchased from 
PBL assay science  (Piscataway Township, NJ).  
 
RNA preparation: RNA was extracted from spleen cells using a TRIzol/RNeasy hybrid 
protocol as described previously [15]. Briefly, an appropriate amount of TRIzol was 
added to the cells and incubated at room temperature for 30 minutes. Choloroform 
(0.2mLs per 1mL of TRIzol) was added and hand shaken for 1 minute. The 
choloroform/TRIzol solution rested at room temperature for 3 minutes before being spun 
at 4°C for 15 minutes. The clear supernatant was removed and mixed with an equal 
volume of cold 70% ethanol. The solution was then added to the Qiagen RNeasy column 
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for further purification via the manufactures instructions. DNA was removed using on 
column digestion with the Qiagen RNAse free DNase kit. RNA was eluted in RNAse free 
water and immediately processed for reverse transcription. 
qPCR: 1ug of RNA was reverse transcribed to cDNA using the iScript Reverse 
Transcription Supermix (Bio-Rad, Hercules, CA). qPCR was preformed on the CFX 
Connect Real-Time system (Bio-rad) using master mixes containing iQ SYBR Green 
Supermix (Bio-rad), nuclease free water, primers (10nM) and cDNA. Primers for Mx-1, 
Cxcl-10, ISG-15 were synthesized by Integrated DNA Technologies (Coralville, Iowa) 
and the IRF-7 and GAPDH primers were purchased from SA Biosciences (Frederick, 
MD). The PCR conditions were 3m at 95°C, 40 cycles of 15s at 95°C, 30s at 60°C, 30s at 
72°C. Melt curve analysis began at 55°C for 10s and increased every 10s by 0.5°C for 80 
cycles.  All samples were performed in triplicate, no-cDNA controls were included for 
each primer, and melt curve analysis was used to determine if the desired product was 
being detected. Expression levels were calculated by comparison to the housekeeping 
gene (GAPDH) for each sample with the Bio-Rad CFX manager software.  
 
ISG15 F 5’ CAG AAF CAF ACT CCT TAA TTC 3’ 
 R 5’ AGA-CCT-CAT-ATA-TGT-TGC-TGT-G 3’ 
Mx-1   F 5’ GAT-CCG-ACT-TCA-CTT-CCA-GAT-GG 3’ 
 R 5’ CAT-CTC-AGT-GGT-AGT-CAA-CCC 3’ 
Cxcl-10  F 5’ GGA TGG CTG TCC TAG CTC TG 
     R 5’ TGA GCT AGG GAG GAC AAG GA 3’ 
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Statistics: Statistical analysis was performed with GraphPad Prism software. Normality 
was assessed. If data was normally distributed, a student’s T-test was used. If data was 
not normally distributed, a Mann-Whitney analysis was used. Data are expressed as mean 
with error bars representing SD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 117!
References 
 
1.! Svenson,!J.L.,!et!al.,!Impact'of'estrogen'receptor'deficiency'on'disease'
expression'in'the'NZM2410'lupus'prone'mouse.!Clin!Immunol,!2008.!128(2):!p.!
259C68.!
2.! Banchereau,!J.,!et!al.,!Immunobiology'of'dendritic'cells.!Annu!Rev!Immunol,!
2000.!18:!p.!767C811.!
3.! Teichmann,!L.L.,!et!al.,!Dendritic'cells'in'lupus'are'not'required'for'activation'of'
T'and'B'cells'but'promote'their'expansion,'resulting'in'tissue'damage.!
Immunity,!2010.!33(6):!p.!967C78.!
4.! Pascual,!V.,!J.!Banchereau,!and!A.K.!Palucka,!The'central'role'of'dendritic'cells'
and'interferonEalpha'in'SLE.!Curr!Opin!Rheumatol,!2003.!15(5):!p.!548C56.!
5.! Banchereau,!J.!and!V.!Pascual,!Type'I'interferon'in'systemic'lupus'
erythematosus'and'other'autoimmune'diseases.!Immunity,!2006.!25(3):!p.!
383C92.!
6.! SantiagoCRaber,!M.L.,!et!al.,!TypeEI'interferon'receptor'deficiency'reduces'
lupusElike'disease'in'NZB'mice.!J!Exp!Med,!2003.!197(6):!p.!777C88.!
7.! Agrawal,!H.,!et!al.,!Deficiency'of'type'I'IFN'receptor'in'lupusEprone'New'Zealand'
mixed'2328'mice'decreases'dendritic'cell'numbers'and'activation'and'protects'
from'disease.!J!Immunol,!2009.!183(9):!p.!6021C9.!
8.! Baccala,!R.,!et!al.,!AntiEIFNEalpha/beta'receptor'antibody'treatment'
ameliorates'disease'in'lupusEpredisposed'mice.!J!Immunol,!2012.!189(12):!p.!
5976C84.!
9.! Sisirak,!V.,!et!al.,!Genetic'evidence'for'the'role'of'plasmacytoid'dendritic'cells'in'
systemic'lupus'erythematosus.!J!Exp!Med,!2014.!
10.! Rowland,!S.L.,!et!al.,!Early,'transient'depletion'of'plasmacytoid'dendritic'cells'
ameliorates'autoimmunity'in'a'lupus'model.!J!Exp!Med,!2014.!
11.! Carreras,!E.,!et!al.,!Estradiol'acts'directly'on'bone'marrow'myeloid'progenitors'
to'differentially'regulate'GMECSF'or'Flt3'ligandEmediated'dendritic'cell'
differentiation.!J!Immunol,!2008.!180(2):!p.!727C38.!
12.! DouinCEchinard,!V.,!et!al.,!Estrogen'receptor'alpha,'but'not'beta,'is'required'for'
optimal'dendritic'cell'differentiation'and'[corrected]'CD40Einduced'cytokine'
production.!J!Immunol,!2008.!180(6):!p.!3661C9.!
13.! PaharkovaCVatchkova,!V.,!R.!Maldonado,!and!S.!Kovats,!Estrogen'preferentially'
promotes'the'differentiation'of'CD11c+'CD11b(intermediate)'dendritic'cells'
from'bone'marrow'precursors.!J!Immunol,!2004.!172(3):!p.!1426C36.!
14.! Carreras,!E.,!et!al.,!Estrogen'receptor'signaling'promotes'dendritic'cell'
differentiation'by'increasing'expression'of'the'transcription'factor'IRF4.!Blood,!
2010.!115(2):!p.!238C46.!
15.! Cunningham,!M.A.,!et!al.,!Estrogen'receptor'alpha'modulates'TollElike'receptor'
signaling'in'murine'lupus.!Clin!Immunol,!2012.!144(1):!p.!1C12.!
16.! Seillet,!C.,!et!al.,!The'TLREmediated'response'of'plasmacytoid'dendritic'cells'is'
positively'regulated'by'estradiol'in'vivo'through'cellEintrinsic'estrogen'receptor'
alpha'signaling.!Blood,!2012.!119(2):!p.!454C64.!
17.! Peter!H!Schur,!M.D.,!D!Gladman,!Overview'of'the'clinical'manifestations'of'
systemic'lupus'erythematosus'in'adults.!2011.!
! 118!
18.! Choi,!J.,!S.T.!Kim,!and!J.!Craft,!The'pathogenesis'of'systemic'lupus'
erythematosusEan'update.!Curr!Opin!Immunol,!2012.!24(6):!p.!651C7.!
19.! Gonzalez,!D.A.,!et!al.,!Sex'hormones'and'autoimmunity.!Immunol!Lett,!2010.!
133(1):!p.!6C13.!
20.! McMurray,!R.W.!and!W.!May,!Sex'hormones'and'systemic'lupus'erythematosus:'
review'and'metaEanalysis.!Arthritis!Rheum,!2003.!48(8):!p.!2100C10.!
21.! Inui,!A.,!et!al.,!Estrogen'receptor'expression'by'peripheral'blood'mononuclear'
cells'of'patients'with'systemic'lupus'erythematosus.!Clin!Rheumatol,!2007.!
26(10):!p.!1675C8.!
22.! Lin,!H.L.,!et!al.,!Estradiol'upregulates'calcineurin'expression'via'overexpression'
of'estrogen'receptor'alpha'gene'in'systemic'lupus'erythematosus.!Kaohsiung!J!
Med!Sci,!2011.!27(4):!p.!125C31.!
23.! Rider,!V.,!et!al.,!Differential'expression'of'estrogen'receptors'in'women'with'
systemic'lupus'erythematosus.!J!Rheumatol,!2006.!33(6):!p.!1093C101.!
24.! SanchezCGuerrero,!J.,!et!al.,!Past'use'of'oral'contraceptives'and'the'risk'of'
developing'systemic'lupus'erythematosus.!Arthritis!Rheum,!1997.!40(5):!p.!
804C8.!
25.! Bernier,!M.O.,!et!al.,!Combined'oral'contraceptive'use'and'the'risk'of'systemic'
lupus'erythematosus.!Arthritis!Rheum,!2009.!61(4):!p.!476C81.!
26.! Petri,!M.,!et!al.,!Combined'oral'contraceptives'in'women'with'systemic'lupus'
erythematosus.!N!Engl!J!Med,!2005.!353(24):!p.!2550C8.!
27.! Colangelo,!K.,!et!al.,!SelfEreported'flaring'varies'during'the'menstrual'cycle'in'
systemic'lupus'erythematosus'compared'with'rheumatoid'arthritis'and'
fibromyalgia.!Rheumatology!(Oxford),!2011.!50(4):!p.!703C8.!
28.! Shabanova,!S.S.,!et!al.,!Ovarian'function'and'disease'activity'in'patients'with'
systemic'lupus'erythematosus.!Clin!Exp!Rheumatol,!2008.!26(3):!p.!436C41.!
29.! Sthoeger,!Z.M.,!H.!Zinger,!and!E.!Mozes,!Beneficial'effects'of'the'antiEoestrogen'
tamoxifen'on'systemic'lupus'erythematosus'of'(NZBxNZW)F1'female'mice'are'
associated'with'specific'reduction'of'IgG3'autoantibodies.!Ann!Rheum!Dis,!
2003.!62(4):!p.!341C6.!
30.! Sturgess,!A.D.,!et!al.,!Effects'of'the'oestrogen'antagonist'tamoxifen'on'disease'
indices'in'systemic'lupus'erythematosus.!J!Clin!Lab!Immunol,!1984.!13(1):!p.!
11C4.!
31.! Zhang,!Y.,!et!al.,!Raloxifene'modulates'estrogenEmediated'B'cell'autoreactivity'
in'NZB/W'F1'mice.!J!Rheumatol,!2010.!37(8):!p.!1646C57.!
32.! Mok,!C.C.,!et!al.,!Effect'of'raloxifene'on'disease'activity'and'vascular'biomarkers'
in'patients'with'systemic'lupus'erythematosus:'subgroup'analysis'of'a'doubleE
blind'randomized'controlled'trial.!Lupus,!2013.!22(14):!p.!1470C8.!
33.! Abdou,!N.I.,!et!al.,!Fulvestrant'(Faslodex),'an'estrogen'selective'receptor'
downregulator,'in'therapy'of'women'with'systemic'lupus'erythematosus.'
clinical,'serologic,'bone'density,'and'T'cell'activation'marker'studies:'a'doubleE
blind'placeboEcontrolled'trial.!J!Rheumatol,!2008.!35(5):!p.!797.!
34.! Chang,!D.M.,!et!al.,!Dehydroepiandrosterone'treatment'of'women'with'mildEtoE
moderate'systemic'lupus'erythematosus:'a'multicenter'randomized,'doubleE
blind,'placeboEcontrolled'trial.!Arthritis!Rheum,!2002.!46(11):!p.!2924C7.!
! 119!
35.! Lahita,!R.G.,!The'role'of'sex'hormones'in'systemic'lupus'erythematosus.!Curr!
Opin!Rheumatol,!1999.!11(5):!p.!352C6.!
36.! Perry,!D.,!et!al.,!Murine'models'of'systemic'lupus'erythematosus.!J!Biomed!
Biotechnol,!2011.!2011:!p.!271694.!
37.! Reizis,!B.,!et!al.,!Plasmacytoid'dendritic'cells:'recent'progress'and'open'
questions.!Annu!Rev!Immunol,!2011.!29:!p.!163C83.!
38.! Merad,!M.,!et!al.,!The'dendritic'cell'lineage:'ontogeny'and'function'of'dendritic'
cells'and'their'subsets'in'the'steady'state'and'the'inflamed'setting.!Annu!Rev!
Immunol,!2013.!31:!p.!563C604.!
39.! KisCToth,!K.!and!G.C.!Tsokos,!Dendritic'cell'function'in'lupus:'Independent'
contributors'or'victims'of'aberrant'immune'regulation.!Autoimmunity,!2010.!
43(2):!p.!121C30.!
40.! Ganguly,!D.,!et!al.,!The'role'of'dendritic'cells'in'autoimmunity.!Nat!Rev!
Immunol,!2013.!13(8):!p.!566C77.!
41.! Chan,!V.S.,!et!al.,!Distinct'roles'of'myeloid'and'plasmacytoid'dendritic'cells'in'
systemic'lupus'erythematosus.!Autoimmun!Rev,!2012.!11(12):!p.!890C7.!
42.! Baccala,!R.,!et!al.,!Essential'requirement'for'IRF8'and'SLC15A4'implicates'
plasmacytoid'dendritic'cells'in'the'pathogenesis'of'lupus.!Proc!Natl!Acad!Sci!U!
S!A,!2013.!110(8):!p.!2940C5.!
43.! Siegal,!F.P.,!et!al.,!The'nature'of'the'principal'type'1'interferonEproducing'cells'
in'human'blood.!Science,!1999.!284(5421):!p.!1835C7.!
44.! Gilliet,!M.,!W.!Cao,!and!Y.J.!Liu,!Plasmacytoid'dendritic'cells:'sensing'nucleic'
acids'in'viral'infection'and'autoimmune'diseases.!Nat!Rev!Immunol,!2008.!
8(8):!p.!594C606.!
45.! Montoya,!M.,!et!al.,!Type'I'interferons'produced'by'dendritic'cells'promote'their'
phenotypic'and'functional'activation.!Blood,!2002.!99(9):!p.!3263C71.!
46.! Baechler,!E.C.,!et!al.,!InterferonEinducible'gene'expression'signature'in'
peripheral'blood'cells'of'patients'with'severe'lupus.!Proc!Natl!Acad!Sci!U!S!A,!
2003.!100(5):!p.!2610C5.!
47.! Sriram,!U.,!et!al.,!Myeloid'dendritic'cells'from'B6.NZM'Sle1/Sle2/Sle3'lupusE
prone'mice'express'an'IFN'signature'that'precedes'disease'onset.!J!Immunol,!
2012.!189(1):!p.!80C91.!
48.! Fairhurst,!A.M.,!et!al.,!Systemic'IFNEalpha'drives'kidney'nephritis'in'B6.Sle123'
mice.!Eur!J!Immunol,!2008.!38(7):!p.!1948C60.!
49.! Crow,!M.K.,!M.!Olferiev,!and!K.A.!Kirou,!Targeting'of'type'I'interferon'in'
systemic'autoimmune'diseases.!Transl!Res,!2015.!165(2):!p.!296C305.!
50.! Kovats,!S.,!Estrogen'receptors'regulate'innate'immune'cells'and'signaling'
pathways.!Cell!Immunol,!2015.!294(2):!p.!63C9.!
51.! Kovats,!S.,!Estrogen'receptors'regulate'an'inflammatory'pathway'of'dendritic'
cell'differentiation:'mechanisms'and'implications'for'immunity.!Horm!Behav,!
2012.!62(3):!p.!254C62.!
52.! Naik,!S.H.,!2010.!595.!
53.! Li,!X.,!et!al.,!17betaEestradiol'enhances'the'response'of'plasmacytoid'dendritic'
cell'to'CpG.!PLoS!One,!2009.!4(12):!p.!e8412.!
54.! Jiang,!B.,!et!al.,!Estrogen'modulates'bone'marrowEderived'DCs'in'SLE'murine'
modelE(NZB'x'NZW)'F1'female'mice.!Immunol!Invest,!2008.!37(3):!p.!227C43.!
! 120!
55.! Couse,!J.F.,!et!al.,!Analysis'of'transcription'and'estrogen'insensitivity'in'the'
female'mouse'after'targeted'disruption'of'the'estrogen'receptor'gene.!Mol!
Endocrinol,!1995.!9(11):!p.!1441C54.!
56.! Seillet,!C.,!et!al.,!Estradiol'promotes'functional'responses'in'inflammatory'and'
steadyEstate'dendritic'cells'through'differential'requirement'for'activation'
functionE1'of'estrogen'receptor'alpha.!J!Immunol,!2013.!190(11):!p.!5459C70.!
57.! Murphy,!A.J.,!et!al.,!Estradiol'regulates'expression'of'estrogen'receptor'
ERalpha46'in'human'macrophages.!PLoS!One,!2009.!4(5):!p.!e5539.!
58.! Pierdominici,!M.,!et!al.,!Estrogen'receptor'profiles'in'human'peripheral'blood'
lymphocytes.!Immunol!Lett,!2010.!132(1C2):!p.!79C85.!
59.! Steinman,!R.M.,!Some'interfaces'of'dendritic'cell'biology.!APMIS,!2003.!111(7C
8):!p.!675C97.!
60.! Chklovskaia,!E.,!et!al.,!CellEsurface'trafficking'and'release'of'flt3'ligand'from'T'
lymphocytes'is'induced'by'common'cytokine'receptor'gammaEchain'signaling'
and'inhibited'by'cyclosporin'A.!Blood,!2001.!97(4):!p.!1027C34.!
61.! Solanilla,!A.,!et!al.,!Expression'of'Flt3Eligand'by'the'endothelial'cell.!Leukemia,!
2000.!14(1):!p.!153C62.!
62.! Lisovsky,!M.,!et!al.,!Flt3Eligand'production'by'human'bone'marrow'stromal'
cells.!Leukemia,!1996.!10(6):!p.!1012C8.!
63.! Fleetwood,!A.J.,!A.D.!Cook,!and!J.A.!Hamilton,!Functions'of'granulocyteE
macrophage'colonyEstimulating'factor.!Crit!Rev!Immunol,!2005.!25(5):!p.!
405C28.!
64.! Shi,!Y.,!et!al.,!GranulocyteEmacrophage'colonyEstimulating'factor'(GMECSF)'and'
TEcell'responses:'what'we'do'and'don't'know.!Cell!Res,!2006.!16(2):!p.!126C33.!
65.! Guermonprez,!P.,!et!al.,!Inflammatory'Flt3l'is'essential'to'mobilize'dendritic'
cells'and'for'T'cell'responses'during'Plasmodium'infection.!Nat!Med,!2013.!
19(6):!p.!730C8.!
66.! Ramos,!M.I.,!et!al.,!FMSErelated'tyrosine'kinase'3'ligand'(Flt3L)/CD135'axis'in'
rheumatoid'arthritis.!Arthritis!Res!Ther,!2013.!15(6):!p.!R209.!
67.! Ramos,!M.I.,!et!al.,!Absence'of'FmsElike'tyrosine'kinase'3'ligand'(Flt3L)'
signalling'protects'against'collagenEinduced'arthritis.!Ann!Rheum!Dis,!2015.!
74(1):!p.!211C9.!
68.! Vermi,!W.,!et!al.,!Cutaneous'distribution'of'plasmacytoid'dendritic'cells'in'lupus'
erythematosus.'Selective'tropism'at'the'site'of'epithelial'apoptotic'damage.!
Immunobiology,!2009.!214(9C10):!p.!877C86.!
69.! Gleisner,!M.A.,!et!al.,!Dendritic'and'stromal'cells'from'the'spleen'of'lupic'mice'
present'phenotypic'and'functional'abnormalities.!Mol!Immunol,!2013.!54(3C
4):!p.!423C34.!
70.! Colonna,!L.,!et!al.,!Abnormal'costimulatory'phenotype'and'function'of'dendritic'
cells'before'and'after'the'onset'of'severe'murine'lupus.!Arthritis!Res!Ther,!
2006.!8(2):!p.!R49.!
71.! Cisse,!B.,!et!al.,!Transcription'factor'E2E2'is'an'essential'and'specific'regulator'
of'plasmacytoid'dendritic'cell'development.!Cell,!2008.!135(1):!p.!37C48.!
72.! Ghosh,!H.S.,!et!al.,!Continuous'expression'of'the'transcription'factor'e2E2'
maintains'the'cell'fate'of'mature'plasmacytoid'dendritic'cells.!Immunity,!2010.!
33(6):!p.!905C16.!
! 121!
73.! Omatsu,!Y.,!et!al.,!Development'of'murine'plasmacytoid'dendritic'cells'defined'
by'increased'expression'of'an'inhibitory'NK'receptor,'Ly49Q.!J!Immunol,!2005.!
174(11):!p.!6657C62.!
74.! Tai,!L.H.,!et!al.,!Positive'regulation'of'plasmacytoid'dendritic'cell'function'via'
Ly49Q'recognition'of'class'I'MHC.!J!Exp!Med,!2008.!205(13):!p.!3187C99.!
75.! Sawai,!C.M.,!et!al.,!Transcription'factor'Runx2'controls'the'development'and'
migration'of'plasmacytoid'dendritic'cells.!J!Exp!Med,!2013.!210(11):!p.!2151C
9.!
76.! Blasius,!A.L.,!et!al.,!Bone'marrow'stromal'cell'antigen'2'is'a'specific'marker'of'
type'I'IFNEproducing'cells'in'the'naive'mouse,'but'a'promiscuous'cell'surface'
antigen'following'IFN'stimulation.!J!Immunol,!2006.!177(5):!p.!3260C5.!
77.! Nakada,!D.,!et!al.,!Oestrogen'increases'haematopoietic'stemEcell'selfErenewal'in'
females'and'during'pregnancy.!Nature,!2014.!505(7484):!p.!555C8.!
78.! Blasius,!A.L.,!et!al.,!SiglecEH'is'an'IPCEspecific'receptor'that'modulates'type'I'
IFN'secretion'through'DAP12.!Blood,!2006.!107(6):!p.!2474C6.!
79.! Swiecki,!M.,!et!al.,!Type'I'interferon'negatively'controls'plasmacytoid'dendritic'
cell'numbers'in'vivo.!J!Exp!Med,!2011.!208(12):!p.!2367C74.!
80.! Palucka,!A.K.,!et!al.,!The'interplay'of'dendritic'cell'subsets'in'systemic'lupus'
erythematosus.!Immunol!Cell!Biol,!2002.!80(5):!p.!484C8.!
81.! Villadangos,!J.A.!and!L.!Young,!AntigenEpresentation'properties'of'
plasmacytoid'dendritic'cells.!Immunity,!2008.!29(3):!p.!352C61.!
82.! Cao,!W.,!et!al.,!TollElike'receptorEmediated'induction'of'type'I'interferon'in'
plasmacytoid'dendritic'cells'requires'the'rapamycinEsensitive'PI(3)KEmTORE
p70S6K'pathway.!Nat!Immunol,!2008.!9(10):!p.!1157C64.!
83.! Rahim,!M.M.,!et!al.,!Ly49Q'positively'regulates'type'I'IFN'production'by'
plasmacytoid'dendritic'cells'in'an'immunoreceptor'tyrosineEbased'inhibitory'
motifEdependent'manner.!J!Immunol,!2013.!190(8):!p.!3994C4004.!
84.! Watarai,!H.,!et!al.,!PDCETREM,'a'plasmacytoid'dendritic'cellEspecific'receptor,'is'
responsible'for'augmented'production'of'type'I'interferon.!Proc!Natl!Acad!Sci!U!
S!A,!2008.!105(8):!p.!2993C8.!
85.! LeibundGutCLandmann,!S.,!et!al.,!MHC'class'II'expression'is'differentially'
regulated'in'plasmacytoid'and'conventional'dendritic'cells.!Nat!Immunol,!
2004.!5(9):!p.!899C908.!
86.! Decker,!P.,!et!al.,!MonocyteEderived'dendritic'cells'overEexpress'CD86'in'
patients'with'systemic'lupus'erythematosus.!Rheumatology!(Oxford),!2006.!
45(9):!p.!1087C95.!
87.! Ding,!D.,!et!al.,!Aberrant'phenotype'and'function'of'myeloid'dendritic'cells'in'
systemic'lupus'erythematosus.!J!Immunol,!2006.!177(9):!p.!5878C89.!
88.! Zhu,!J.,!et!al.,!T'cell'hyperactivity'in'lupus'as'a'consequence'of'hyperstimulatory'
antigenEpresenting'cells.!J!Clin!Invest,!2005.!115(7):!p.!1869C78.!
89.! Kwok,!S.K.,!et!al.,!Dysfunctional'interferonEalpha'production'by'peripheral'
plasmacytoid'dendritic'cells'upon'TollElike'receptorE9'stimulation'in'patients'
with'systemic'lupus'erythematosus.!Arthritis!Res!Ther,!2008.!10(2):!p.!R29.!
90.! Ma,!D.Y.!and!E.A.!Clark,!The'role'of'CD40'and'CD154/CD40L'in'dendritic'cells.!
Semin!Immunol,!2009.!21(5):!p.!265C72.!
! 122!
91.! MarshakCRothstein,!A.,!TollElike'receptors'in'systemic'autoimmune'disease.!Nat!
Rev!Immunol,!2006.!6(11):!p.!823C35.!
92.! Fairhurst,!A.M.,!et!al.,!Type'I'interferons'produced'by'resident'renal'cells'may'
promote'endEorgan'disease'in'autoantibodyEmediated'glomerulonephritis.!J!
Immunol,!2009.!183(10):!p.!6831C8.!
93.! Nie,!Y.J.,!et!al.,!Phenotypic'and'functional'abnormalities'of'bone'marrowE
derived'dendritic'cells'in'systemic'lupus'erythematosus.!Arthritis!Res!Ther,!
2010.!12(3):!p.!R91.!
94.! Christensen,!S.R.,!et!al.,!TollElike'receptor'7'and'TLR9'dictate'autoantibody'
specificity'and'have'opposing'inflammatory'and'regulatory'roles'in'a'murine'
model'of'lupus.!Immunity,!2006.!25(3):!p.!417C28.!
95.! Schneider,!W.M.,!M.D.!Chevillotte,!and!C.M.!Rice,!InterferonEstimulated'genes:'
a'complex'web'of'host'defenses.!Annu!Rev!Immunol,!2014.!32:!p.!513C45.!
96.! Diebold,!S.S.,!et!al.,!Viral'infection'switches'nonEplasmacytoid'dendritic'cells'
into'high'interferon'producers.!Nature,!2003.!424(6946):!p.!324C8.!
97.! KlesneyCTait,!J.,!I.R.!Turnbull,!and!M.!Colonna,!The'TREM'receptor'family'and'
signal'integration.!Nat!Immunol,!2006.!7(12):!p.!1266C73.!
98.! Keyes,!K.T.,!et!al.,!Pharmacological'inhibition'of'PTEN'limits'myocardial'infarct'
size'and'improves'left'ventricular'function'postinfarction.!Am!J!Physiol!Heart!
Circ!Physiol,!2010.!298(4):!p.!H1198C208.!
99.! Sun,!M.,!et!al.,!PhosphatidylinositolE3EOH'Kinase'(PI3K)/AKT2,'activated'in'
breast'cancer,'regulates'and'is'induced'by'estrogen'receptor'alpha'(ERalpha)'
via'interaction'between'ERalpha'and'PI3K.!Cancer!Res,!2001.!61(16):!p.!5985C
91.!
100.! Weichhart,!T.!and!M.D.!Saemann,!The'PI3K/Akt/mTOR'pathway'in'innate'
immune'cells:'emerging'therapeutic'applications.!Ann!Rheum!Dis,!2008.!67+
Suppl+3:!p.!iii70C4.!
101.! van!de!Laar,!L.,!et!al.,!PI3KEPKB'hyperactivation'augments'human'
plasmacytoid'dendritic'cell'development'and'function.!Blood,!2012.!120(25):!
p.!4982C91.!
102.! Kazi,!A.A.,!K.H.!Molitoris,!and!R.D.!Koos,!Estrogen'rapidly'activates'the'
PI3K/AKT'pathway'and'hypoxiaEinducible'factor'1'and'induces'vascular'
endothelial'growth'factor'A'expression'in'luminal'epithelial'cells'of'the'rat'
uterus.!Biol!Reprod,!2009.!81(2):!p.!378C87.!
103.! Stylianou,!K.,!et!al.,!The'PI3K/Akt/mTOR'pathway'is'activated'in'murine'lupus'
nephritis'and'downregulated'by'rapamycin.!Nephrol!Dial!Transplant,!2011.!
26(2):!p.!498C508.!
104.! Fernandez,!D.,!et!al.,!Rapamycin'reduces'disease'activity'and'normalizes'T'cell'
activationEinduced'calcium'fluxing'in'patients'with'systemic'lupus'
erythematosus.!Arthritis!Rheum,!2006.!54(9):!p.!2983C8.!
105.! Warner,!L.M.,!L.M.!Adams,!and!S.N.!Sehgal,!Rapamycin'prolongs'survival'and'
arrests'pathophysiologic'changes'in'murine'systemic'lupus'erythematosus.!
Arthritis!Rheum,!1994.!37(2):!p.!289C97.!
106.! Lai,!Z.W.,!et!al.,!NEacetylcysteine'reduces'disease'activity'by'blocking'
mammalian'target'of'rapamycin'in'T'cells'from'systemic'lupus'erythematosus'
! 123!
patients:'a'randomized,'doubleEblind,'placeboEcontrolled'trial.!Arthritis!
Rheum,!2012.!64(9):!p.!2937C46.!
107.! Puri,!J.,!et!al.,!Estrogen'and'inflammation'modulate'estrogen'receptor'alpha'
expression'in'specific'tissues'of'the'temporomandibular'joint.!Reprod!Biol!
Endocrinol,!2009.!7:!p.!155.!
108.! Baumgarten,!S.C.!and!J.!Frasor,!Minireview:'Inflammation:'an'instigator'of'
more'aggressive'estrogen'receptor'(ER)'positive'breast'cancers.!Mol!
Endocrinol,!2012.!26(3):!p.!360C71.!
109.! Bezwoda,!W.R.!and!K.!Meyer,!Effect'of'alphaEinterferon,'17'betaEestradiol,'and'
tamoxifen'on'estrogen'receptor'concentration'and'cell'cycle'kinetics'of'MCF'7'
cells.!Cancer!Res,!1990.!50(17):!p.!5387C91.!
110.! Panchanathan,!R.,!et!al.,!Mutually'positive'regulatory'feedback'loop'between'
interferons'and'estrogen'receptorEalpha'in'mice:'implications'for'sex'bias'in'
autoimmunity.!PLoS!One,!2010.!5(5):!p.!e10868.!
111.! Li,!L.,!M.P.!Haynes,!and!J.R.!Bender,!Plasma'membrane'localization'and'
function'of'the'estrogen'receptor'alpha'variant'(ER46)'in'human'endothelial'
cells.!Proc!Natl!Acad!Sci!U!S!A,!2003.!100(8):!p.!4807C12.!
112.! Figtree,!G.A.,!et!al.,!Truncated'estrogen'receptor'alpha'46EkDa'isoform'in'
human'endothelial'cells:'relationship'to'acute'activation'of'nitric'oxide'
synthase.!Circulation,!2003.!107(1):!p.!120C6.!
 
